Nobilis Health (NRTSF) 10-K 2 Apr 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 25, 2015	Jun. 30, 2014
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Trading Symbol	nhc
Entity Registrant Name	Nobilis Health Corp.
Entity Central Index Key	1409916
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		61,135,631
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Entity Public Float			$23,254,102
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current Assets:
Cash	$7,568	$5,602
Trade accounts receivable, net	42,175	8,281
Medical supplies	1,412	787
Prepaid expenses and other current assets	3,554	540
Total current assets	54,709	15,210
Property and equipment, net	9,087	4,833
Intangible assets	19,543	1,097
Goodwill	22,470	1,228
Notes receivable	659	150
Investments in associates	880	0
Other long-term assets	234	121
Total Assets	107,582	22,639
Current Liabilities:
Trade accounts payable	10,528	3,018
Accrued liabilities	9,112	1,970
Lines of credit	5,420	0
Subordinated notes payable	635	0
Current portion of debt	3,437	1,693
Current portion of capital leases	257	49
Other current liabilities	1,485	43
Total current liabilities	30,874	6,773
Long-term capital leases, net of current portion	573	163
Long-term debt, net of current portion	10,582	0
Other long-term liabilities	252	0
Total liabilities	42,281	6,936
Shareholders' Equity:
Common stock, no par value	0	0
Additional paid in capital	179,293	150,897
Accumulated deficit	-132,866	-140,052
Accumulated other comprehensive income	-111	104
Total shareholders' equity attributable to Nobilis Health Corp.	46,316	10,949
Noncontrolling interests	18,985	4,754
Total shareholders' equity	65,301	15,703
Total Liabilities and Shareholders' Equity	$107,582	$22,639

Consolidated_Statements_of_Ear

Consolidated Statements of Earnings (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Revenues:
Patient and net professional fees	$80,917	$31,128
Contracted marketing revenues	2,171	0
Factoring revenues	941	0
Total revenue	84,029	31,128
Cost of revenues	201	0
Gross Profit	83,828	31,128
Income from operations	20,833	4,676
Other expense (income):
Gain on bargain purchase	0	-2,392
Interest expense	288	97
Other expense (income), net	-183	120
Total other expense (income)	105	-2,175
Net income before income taxes and noncontrolling interests	20,728	6,851
Income tax	480	177
Net income	20,248	6,674
Net income attributable to noncontrolling interests	13,062	5,476
Net income attributable to Nobilis Health Corp.	7,186	1,198
Net income per basic common share	$0.15	$0.03
Net income per fully diluted common share	$0.15	$0.03
Weighted average shares outstanding (basic)	46,517,815	36,793,950
Weighted average shares outstanding (fully diluted)	48,781,348	37,637,662
Operating expenses [Member]
Revenues:
Salaries and benefits	11,933	5,329
Drugs and supplies	11,094	4,423
General and administrative	31,791	10,648
Depreciation and amortization	1,529	650
Total operating expenses	56,347	21,050
Corporate costs [Member]
Revenues:
Salaries and benefits	2,386	2,285
General and administrative	4,082	2,228
Legal expenses	66	808
Depreciation and amortization	114	81
Total operating expenses	$6,648	$5,402

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Net income	$7,186	$1,198
Other comprehensive income:
Foreign currency translation adjustments	-215	-32
Total other comprehensive income	-215	-32
Comprehensive income attributable to Nobilis Health Corp.	$6,971	$1,166

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Equity (USD $)	Additional Paid In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income [Member]	Equity Attibutable to Nobilis Health [Member]	Equity Attributable to Noncontrolling Interests [Member]	Total
In Thousands
Beginning Balance at Dec. 31, 2012	$145,802	($141,250)	$136	$4,688	$4,462	$9,150
Net income		1,198		1,198	5,476	6,674
Proceeds from private equity offering	4,089			4,089		4,089
Proceeds from sale of ownership interest in subsidiary	303			303		303
Purchase of additional ownership interest in subsidiary	157			157	-927	-770
Distributions to noncontrolling interests					-4,257	-4,257
Other comprehensive income			-32	-32		-32
Subtotal	150,351	-140,052	104	10,403	4,754	15,157
Exercise of stock options	168			168		168
Share-based compensation, net	378			378		378
Ending Balance at Dec. 31, 2013	150,897	-140,052	104	10,949	4,754	15,703
Net income		7,186		7,186	13,062	20,248
Proceeds from private equity offering	6,100			6,100		6,100
Proceeds from sale of ownership interest in subsidiary	705			705		705
Purchase of additional ownership interest in subsidiary						0
Purchase of investment	490			490		490
Consolidation of investment					522	522
Consolidation of First Nobilis					7,206	7,206
Acquisition of Athas Health	16,239			16,239		16,239
Distributions to noncontrolling interests					-6,559	-6,559
Other comprehensive income			-215	-215		-215
Subtotal	174,431	-132,866	-111	41,454	18,985	60,439
Exercise of stock warrants	3,188			3,188		3,188
Exercise of stock options	166			166		166
Share-based compensation, net	1,508			1,508		1,508
Ending Balance at Dec. 31, 2014	$179,293	($132,866)	($111)	$46,316	$18,985	$65,301

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$7,186	$1,198
Adjustments to reconcile net income attributable to Nobilis to net cash provided by operating activities:
Depreciation	1,642	731
Gain on sale of fixed assets	-39	-2
Noncontrolling interests	13,062	5,476
Gain on bargain purchase of a business	0	-2,392
Foreign currency gain (loss)	-215	-32
Share-based compensation	1,508	378
Changes in operating assets and liabilities	-19,146	-1,869
Net cash provided by operating activities	3,998	3,488
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	-2,023	-1,180
Purchase of investment in associate	-150	0
Purchase of interest acquired in a subsidiary	-346	0
Distributions from investments in associates	0	159
Proceeds from sale of property and equipment	39	2
Proceeds from sale of ownership interests of subsidiary	705	303
Purchase of additional ownership interest in subsidiary	0	-770
Acquisition of a business	-3,000	-460
Net cash (used for) investing activities	-4,775	-1,946
CASH FLOWS FROM FINANCING ACTIVITIES:
Distributions to non controlling interests	-6,559	-4,257
Proceeds from exercise of stock options	166	168
Proceeds from exercise of stock warrants	3,188	0
Payments on capital lease obligations	-77	-12
Proceeds from debt and lines of credit	1,300	0
Payments of debt and lines of credit	-1,375	0
Note receivable	0	-150
Proceeds from private placement	6,100	4,089
Net cash provided by (used for) financing activities	2,743	-162
NET INCREASE IN CASH AND CASH EQUIVALENTS	1,966	1,380
CASH AND CASH EQUIVALENTS - Beginning of period	5,602	4,222
CASH AND CASH EQUIVALENTS - End of period	7,568	5,602
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for taxes	165	100
Cash paid for interest	216	97
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Capital expenditures funded by capital lease borrowings	696	224
Non-cash acquisition of property and equipment	2,271	0
Non-cash acquisition of intangibles and goodwill	$7,206	$0

Company_Description

Company Description	12 Months Ended
	Dec. 31, 2014
Company Description [Text Block]	1. Company Description
	Nobilis Health Corp. was incorporated on March 16, 2007 under the name "Northstar Healthcare Inc." pursuant to the provisions of the British Columbia Business Corporations Act ("BCBCA" ) . On December 5, 2014, Northstar Healthcare Inc. changed its name to Nobilis Health Corp. Our registered office is located at Suite 400, 570 Granville Street, Vancouver, British Columbia V6C 3P1 and our corporate office is located at 4120 Southwest Freeway, Suite 150, Houston, Texas 77027. Our common shares are and have been publicly traded on the Toronto Stock Exchange under the symbol "NHC" since May 2007.
	We own and manage nine healthcare facilities (the "Nobilis Facilities") in Texas and Arizona; two MRI centers, an urgent care center, one hospital and five ambulatory surgery centers (“ASC”), referred to as the "Nobilis ASCs" of which three are located in Houston, Texas, one in Dallas, Texas and one in Scottsdale, Arizona. The Nobilis ASCs are licensed ambulatory surgery centers that provide scheduled surgical procedures in a limited number of clinical specialties, which enables them to develop routines, procedures and protocols to maximize operating efficiency and productivity while offering an enhanced healthcare experience for both physicians and patients.
	The Nobilis ASCs do not offer the full range of services typically found in traditional hospitals, but instead focus on certain clinical specialties, including orthopedic surgery, podiatric surgery, ENT, pain management, gastro- intestinal, gynecology, and general surgery. Nobilis’ hospital focuses on these same specialties with the ability to take on more complex instances.
	In December 2014, the Company expanded its services to health care marketing and factoring of receivables when it acquired 100% interests of Athas Health, LLC (“Athas”).

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Summary of Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies
	Basis of Presentation
	The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
	Principles of Consolidation
	Our consolidated financial statements include the accounts of Nobilis and its subsidiaries. Subsidiaries are all entities over which the Company has the power to govern the financial and operating policies through ownership of more than one half of the voting rights or by determining that the subsidiary is a variable interest entity (“VIE”) that requires consolidation. A reporting entity with a controlling financial interest in a VIE will have both of the following characteristics: (i) the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance and (ii) the obligation to absorb the losses of the VIE that could potentially be significant to the VIE or the right to receive benefit from the VIE that could potentially be significant to the VIE. See note 17 for details. All significant intercompany accounts are eliminated in consolidation.
	Use of Accounting Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Retroactively calculated third-party contractual adjustments are accrued on an estimated basis in the period in which the related services are rendered. Net patient service revenue is adjusted as required in subsequent periods based on final settlements and collections.
	Cash
	We maintain our cash in bank deposit accounts that at times, may exceed federally insured limits. We have not experienced any losses in such accounts, and we believe we are not exposed to any significant credit risks on cash. At December 31, 2014 and 2013, our cash exceeded what is federally insured.
	Patient and Net Professional Fees
	Patient and net professional fees is reported at the estimated net realizable amounts from patients, third-party payors, and others for services rendered.
	The amounts actually collected by the Company from third-party payors, including private insurers, are variable, even for identical procedures performed. An additional factor in the determination of patient and net professional fees is the Company’s payor mix, as between private health insurance plans, workers’ compensation, directly from patients, and from government payor plans. Management reviews and evaluates historical payment data, payor mix and current economic conditions on a periodic basis and adjusts the estimated collections as a percentage of gross billings (which are used to determine patient and net professional fees) as required in subsequent periods based on final settlements and collections.
	Revenue is recognized upon the performance of the patient service and when ultimate collection is measurable and reasonably assured.
	Contracted Marketing Revenues
	Contracted marketing revenue is comprised of payments from hospitals, ASC’s and other ancillary service providers through marketing services agreements. The services include licensing, marketing, patient intake, patient outcome assessments and educational services. Revenue is recognized on a gross basis upon the performance of the marketing service and when ultimate collection is measurable and reasonably assured. Costs associated with the performance of these services is recorded in cost of revenue in the consolidated statement of earnings.
	Factoring Revenues
	Factoring revenue is comprised of revenue generated from certain accounts receivables which are purchased from third parties through the regular course of business. Purchase price is determined either by a flat fee per case, as dictated per the agreement, or as a percentage of final collections. At the time of purchase, the Company assumes all financial risk and incurs all costs related to collections without any recourse to the third party seller. Revenue is recognized based upon the date of the original service associated with the receivable.
	Accounts Receivable
	Accounts receivable consists of net patient service revenues and factoring revenues recorded at net realizable value and contracted marketing revenues recorded at the fees due from the facilities for marketing services performed.
	On a periodic basis, we evaluate receivables based on the age of the receivable, history of past collections and current credit and economic conditions and adjust the carrying value accordingly. An account is written off when it is determined that all collection efforts have been exhausted. The Company does not accrue finance or interest charges on accounts receivable. An allowance for uncollectible patient receivables balances, including receivables from non-partner surgeons, is maintained at a level which the Company believes is adequate to absorb possible losses.
	Medical Supplies
	Medical supplies consist of various surgical supplies and medications and are valued at the lower of cost or market on the first-in, first-out method. The market value of inventories is determined based on the estimated selling price in the ordinary course of business less the estimated costs of sale, and a reasonable profit margin based on the effort required sell the inventories. The Company had no write-downs for medical supplies for the years ended December 31, 2014 or 2013.
	Property and Equipment
	Property and equipment is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets. Property under capital leases and the related obligation for future lease payments are initially recorded at an amount equal to the lesser of fair value of the property and equipment or the present value of the future lease payments. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to operations when incurred.
	We evaluate our long-lived assets for possible impairment annually or whenever events or changes in circumstances indicate that the carrying amount of the asset, or related group of assets, may not be recoverable from estimated future undiscounted cash flows. If the estimated future undiscounted cash flows are less than the carrying value of the assets, we calculate the amount of impairment if the carrying value of the long-lived assets exceeds the fair value of the assets. The fair value of the assets is estimated based on appraisals, established market values of comparable assets or internal estimates of future net cash flows expected to result from the use and ultimate disposition of the asset. The estimates of these future cash flows are based on assumptions and projections we believe to be reasonable and supportable. They require our subjective judgments and take into account assumptions about revenue and expense growth rates. These assumptions may vary by type of facility and presume stable, improving or, in some cases, declining results at our hospitals, depending on their circumstances.
	We report long-lived assets to be disposed of at the lower of their carrying amounts or fair values less costs to sell. In such circumstances, our estimates of fair value are based on appraisals, established market prices for comparable assets or internal estimates of future net cash flows. Gains and losses on disposals of property and equipment are determined by comparing the proceeds from disposal with the net carrying amount of property and equipment, and are recognized within other expense (income) in the consolidated statement of earnings.
	The estimated useful lives for depreciation purposes are as follows:
	Property and Equipment	Estimated Useful Lives
	Telephone equipment	7 Years
	Computer hardware	5 Years
	Computer software	3 - 5 Years
	Furniture and office equipment	7 Years
	Medical equipment	5 Years
	Leasehold improvements	Estimated usefule life or lease term
	I nvestments in Associates
	Investments in associates which are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an associate depends on an evaluation of several factors including, among others, representation on the associate’s board of directors, involvement in operations, and ownership level. Under the equity method of accounting, the associate’s accounts are not reflected within the Company’s consolidated balances sheets and statements of earnings; however, the Company’s share of the earnings or losses of the associate is reflected in other expense (income) in the consolidated statements of earnings. The Company’s carrying value in an equity method investment is reflected in investments in associates in the consolidated balance sheets.
	When the Company’s carrying value in an equity method investment is reduced to zero, no further losses are recorded in the Company’s consolidated financial statements unless the Company guaranteed obligations of the associate or has committed additional funding. When the associate subsequently reports income, the Company will not record its share of such income until it equals the amount of its share of losses not previously recognized.
	Investments in associates which are not accounted for under the equity method of accounting are accounted for under the cost method of accounting and are initially recognized at cost. Distributions received from an associate are recorded as other expense (income) in the consolidated statements of earnings. Under this method, the Company’s share of the earnings or losses of the associates is not included in the consolidated balance sheets or consolidated statements of earnings. However, the investments are reviewed for impairment at least annually and any impairment loss that is other than temporary is recognized in the consolidated statements of earnings. If circumstances suggest that the value of the associate has subsequently recovered, such recovery is not recorded. At December 31, 2014, the investments are not considered impaired.
	Goodwill and Intangibles
	Goodwill represents the excess of the cost of an acquisition over the fair value of the Company’s share of the net identifiable assets of an acquired subsidiary on the date of acquisition. Goodwill is reviewed for impairment on an annual basis or more frequently if events or circumstances indicate potential impairment. The Company’s goodwill evaluation is based on both qualitative and quantitative assessments regarding the fair value of goodwill relative to its carrying value. The Company assesses qualitative factors to determine if its sole reporting unit’s fair value is more likely than not to exceed its carrying value, including goodwill. In the event the Company determines that it is more likely than not that its reporting unit’s fair value is less than its carrying amount, quantitative testing is performed comparing recorded values to estimated fair values. Estimates of fair value are based on appraisals, established market prices for comparable assets or internal estimates of future net cash flows. If the fair value exceeds the carrying value, goodwill is not impaired. If the carrying value exceeds the fair value, an impairment charge is recognized through a charge to operations based upon the excess of the carrying value of goodwill over the implied fair value.
	Indefinite life intangible assets consisting of trade names, trademarks, Medicare licenses, and an unfavorable lease, are not amortizable; however, are evaluated for impairment on an annual basis. Definite live intangible assets consisting of non-compete agreements, internally developed software, trade secret methodology and physician relationships, are carried at cost less accumulated amortization, which is calculated on a straight-line basis over a period of five to 20 years depending on the asset’s useful life.
	Advertising and Marketing Costs
	Advertising costs are expensed as they are incurred. Advertising expense for the years ended December 31, 2014 and 2013 was $9.9 million and $3.2 million, respectively. The Company utilizes many media outlets for marketing to patients which include internet, TV, radio, print, seminar and billboard advertising.
	Income Taxes
	The tax expense for the period comprises current and deferred tax. Tax expense is recognized in the consolidated statement of earnings, except to the extent that it relates to items recognized directly in equity. For items recognized directly in equity, the tax expense is also recognized in equity.
	The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date in the countries where the Company’s subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulations is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.
	Deferred income tax is recognized, using the liability method, on temporary differences arising between the tax basis of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.
	Deferred income tax assets are recognized only to the extent that it is probable that future taxable profit will be available against which the temporary difference can be utilized.
	Deferred income tax is provided on temporary differences arising on investments in subsidiaries and associates, except where the timing of the reversal of the temporary difference is controlled by the Company and it is probable that the temporary difference will not reverse in the foreseeable future.
	Under U.S. GAAP, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty (50) percent likelihood of being realized upon ultimate settlement. The Company annually evaluates tax positions to determine the need for any additional disclosures in accordance with U.S. GAAP, including de-recognition, classification, interest and penalties on income taxes and accounting in interim periods.
	Leases
	Certain leases are classified as capital leases whenever the terms of the lease transfer substantially all of the risks and rewards of ownership to the lessee. Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases (net of any incentives received from the lessor) are charged to the consolidated statement of earnings on a straight-line basis over the period of the lease as rent expense.
	Foreign Currency
	Items included in the consolidated financial statements for each of the Company’s entities are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). Currently, all of the Company’s activities are measured using the U.S. Dollar (“USD”). The consolidated statements are presented in USD, the Company’s reporting currency.
	From time to time monetary assets and liabilities may be denominated in foreign currency, and, if so, will be translated at the exchange rate in effect as the statement of financial position date, with resulting gains or losses included within the consolidated statement of comprehensive income. Revenues and expenses denominated in foreign currencies are translated into USD at the average foreign currency exchange rate for the period.
	Share Based Compensation
	The Company recognizes all stock-based payments to employees, including grants of employee stock options, in the consolidated financial statements based on their grant-date fair values in accordance with U.S GAAP. The Company values its stock options awarded using the Black-Scholes option pricing model. Restricted stock awards are valued at the grant date closing market price. Stock based compensation costs are recognized over the vesting period, which is the period during which the employee is required to provide service in exchange for the award. Stock-based compensation paid to non-employees are valued at the fair value at the applicable measurement date and charged to expense as services are rendered.
	Net Income Per Common Share
	We calculate net income per common share by dividing net income available for common shareholders by the weighted average number of common shares outstanding during the period. Fully diluted income per share is computed using the weighted average number of common and potential common shares outstanding during the period. Potential common shares include those that may be issued upon redemption of units granted under the Company’s RSU and Share Option Plans.
	Comprehensive Income
	Comprehensive income consists of net income and other gains and losses affecting stockholder's equity that are excluded from net income, such as unrealized gains and losses on available-for-sale investments, foreign currency translation gains and losses and minimum pension liability. The Company’s other comprehensive income represents foreign currency translation adjustments.
	Noncontrolling Interests
	Noncontrolling interests are classified in the consolidated statements of earnings as part of consolidated net income and the accumulated amount of noncontrolling interest in the consolidated balance sheets as part of shareholders’ equity. Changes in the ownership interest in a consolidated subsidiary that does not result in a loss of control are accounted for as an equity transaction. If a change in ownership of a consolidated subsidiary results in a loss of control and deconsolidation, any retained ownership interests are remeasured with the gain or loss reported in net earnings.
	Segment Reporting
The Company reports segment information based on how the chief operating decision maker, along with other members of management, organize and utilize financial and operational data in determining how to allocate resources and assess performance.
Effective December 1, 2014, the Company’s business lines are classified into two reportable business segments which include a medical services segment and a marketing and factoring segment. The medical services segment provides the operation of hospitals, outpatient facilities and other various related health care services. The marketing and factoring segment provides direct to consumer marketing efforts which educate patients on their healthcare options. Factoring activities are included in the marketing segment, as such activities only pertain to patients which are acquired through the marketing efforts of Athas.
We evaluate performance based on income from operations of the respective business units prior to the allocation of corporate office expenses. Transactions between segments are eliminated in consolidation. Our corporate office provides general and administrative as well as support services to our two revenue-generating segments. Management allocates costs between segments for selling, general and administrative expenses and depreciation expense.
Recent Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board (“FASB”) issued new guidance that introduces a new five-step revenue recognition model in which an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance also requires disclosures sufficient to enable users to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers, including qualitative and quantitative disclosures about contracts with customers, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This standard is effective for fiscal years beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently evaluating the new guidance to determine the impact it will have on its consolidated financial statements.
In June 2014, the FASB issued amended guidance on the accounting for certain share-based employee compensation awards. The amended guidance applies to share-based employee compensation awards that include a performance target that affects vesting when the performance target can be achieved after the requisite service period. These targets are to be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant-date fair value of the award and compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved. The amendments are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. The Company does not expect adoption will have a material impact on its consolidated financial statements.
In February 2015, the FASB issued amended guidance on the consolidation of legal entities including limited partnerships and limited liability corporations. The guidance modifies the consolidation models to be analyzed in determining whether a reporting entity should consolidate certain types of legal entities. The guidance must be applied using on of two retrospective application methods and will be effective for fiscal years beginning after December 15, 2015, and for interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The Company does not expect adoption will have a material impact on its consolidated financial statements.

Acquisitions_and_Business_Comb

Acquisitions and Business Combinations	12 Months Ended
	Dec. 31, 2014
Acquisitions and Business Combinations [Text Block]	3. Acquisitions and Business Combinations
	In December 2013, the Company completed its acquisition of a former outpatient surgery center near Phoenix, Arizona. The acquisition was completed through bankruptcy court. The Company created a new subsidiary named Northstar Healthcare Surgery Center – Scottsdale, LLC and will continue to operate the surgery center in a similar capacity.
	The Company concluded that the fair value of the consideration transferred in the acquisition was less than the fair value of the net identifiable assets acquired, resulting in $2.4 million gain recognized in connection with the acquisition. The gain from a bargain purchase has been presented in a separate line item in the accompanying consolidated statements of earnings.
	The costs related to the transaction were $0.1 million and were expensed during the year ended December 31, 2013.
	The following table summarizes the fair values of the identifiable assets acquired at the date of acquisition:
			16-Dec-13
	Furniture and office equipment	$	131
	Medical equipment		495
	Leasehold improvements		2,226
	Net assets acquired		2,852
	Less : gain from bargain purchase		(2,392	)
	Total pu rchase price	$	460
	In January 2014, the Company acquired an ownership interest in two imaging centers and one urgent care clinic in Houston. The aggregate cost of the acquisition is comprised of $0.3 million in cash, net of acquired cash, and 431,711 shares of Nobilis stock representing a combined value of $0.9 million.
	The following table summarizes the fair values of the identifiable assets acquired and liabilities assumed at the date of acquisition:
			16-Jan-14
	Assets:
	Property and equipment	$	2,271
	Prepaid expenses and other assets		129
	Goodwill		701
	Assets acquired	$	3,101
	Liabilities:
	Accounts payable	$	697
	Debt		1,544
	Liabilities assumed	$	2,241
	Consideration:
	Cash, net of cash acquired	$	346
	Stock issued for acquisition		514
	Total Consideration	$	860
	First Nobilis, LLC
	In September 2014, the Company formed First Nobilis, LLC, a Texas limited liability Company (“First Nobilis”). First Nobilis is owned 51% by the Company and 49% by a third party. First Nobilis formed two subsidiary Texas limited liability companies to be the new operating entities.
	Upon formation of First Nobilis, effective September 1, 2014, Nobilis contributed $7.5 million in cash to the new entity. For a 49% ownership interest, a third party contributed medical supplies, intangible assets, and certain accounts payables and accounts receivables. This transaction was treated as a business combination. The fair value of the intangible assets and liabilities acquired were determined by independent third party valuation experts. The carrying amounts of all other net assets acquired approximate their fair values due to their short term nature.
	The following table summarizes the fair values of the identifiable assets acquired and liabilities assumed at the date of acquisition:
			1-Sep-14
	Assets:
	Accounts receivable	$	6,509
	Medical supplies		598
	Trade name		1,200
	Physician relationships		4,000
	Goodwill		1,249
	Assets acquired	$	13,556
	Liabilities:
	Accounts payable	$	6,060
	Unfavorable lease		290
	Liabilities assumed	$	6,350
	Athas
	On December 1, 2014, the Company completed its acquisition of Athas for total consideration of approximately $31.2 million (all $ denominations in US dollars). Athas is based in Dallas, Texas, and focuses on the delivery of specialized healthcare services in seven states through the use of contracted marketing services and factoring of receivables. The purchase price for Nobilis to acquire all of the ownership interests in Athas was broken down as follows: $3.0 million in cash upon closing, the issuance of a promissory note by Nobilis to the sellers for $12.0 million, the issuance at closing of 6,666,666 shares of Nobilis common stock that are subject to a lock up of up to two years, and the issuance of an additional 4,666,666 shares of Nobilis common stock issued over two years with half issued on the first anniversary of the closing and the second half issued on the second anniversary of the closing. Under the two year lock up period, the stock issued as part of the purchase price is subject to restrictions on transfer and may not be sold or pledged until the lock out period is released.
	The fair value of the intangible assets acquired were determined by independent third party valuation experts. The carrying amounts of all other net assets acquired approximate their fair values due to their short term nature. The value of the stock issued for consideration was determined by third party valuation experts using the published stock price on the date of closing, less a discount for lack of marketability as a result of the two year lock up period on the shares issued.
	Subsequent to the acquisition date of December 1, 2014, Athas had $3.4 million in revenues and $1.3 million of net income which is included in the Company’s December 31, 2014 consolidated statements of earnings.
	The costs related to the transaction were $0.1 million and were expensed during the year ended December 31, 2014. These costs are included in corporate general and administrative expenses in the December 31, 2014 consolidated statements of earnings.
	The following table summarizes the fair values of the identifiable assets acquired and liabilities assumed at the date of acquisition:
			1-Dec-14
	Assets:
	Cash	$	(53	)
	Trade accounts receivable		6,427
	Other receivable		450
	Prepaid expenses		226
	Investments in associates		730
	PP&E		752
	Trademark		4,770
	Internally developed software		1,980
	Non-compete agreements		1,820
	Trade secret methodology		5,120
	Goodwill		19,292
	Assets acquired	$	41,514
Liabilities
Trade accounts payable	$	1,531
Accrued liabilities		3,470
Line of credit		4,120
Subordinated notes payable		635
Debt		157
Other current liabilities		102
Other long-term liabilities		260
Liabilities assumed	$	10,275
Consideration:
Cash, net of cash acquired	$	3,000
Debt issued for consideration		12,000
Stock issued for consideration		16,239
Total consideration	$	31,239
The following summarized pro forma information for the years ended December 31, 2014 and 2013 presents the combined results of the Company as if the business combinations occurred as of January 1, 2013.
		Nobilis Health			First Surgical			Athas			Consolidated
31-Dec-14
Revenue	$	84,029		$	17,577		$	26,059		$	127,665
Net income before noncontrolling interests		20,247			(3,364	)		(1,481	)		15,402
Net income attributable to noncontrolling interests		13,062			(1,275	)		-			11,787
Net income (loss) attributable to Nobilis Health Corp.	$	7,185		$	(2,089	)	$	(1,481	)	$	3,615
31-Dec-13
Revenue	$	31,128		$	32,327		$	22,731		$	86,186
Net income before noncontrolling interests		6,674			(677	)		(139	)		5,858
Net income attributable to noncontrolling interests		5,476			2,265			-			7,741
Net income (loss) attributable to Nobilis Health Corp.	$	1,198		$	(2,942	)	$	(139	)	$	(1,883	)
The pro forma financial information has been prepared for comparative purposes only and does not purport to be indicative of the actual operating results that would have been recorded had the business combinations actually taken place at the beginning of the fiscal year 2013, and should not be taken as indicative of future consolidated operating results. Additionally, the pro forma financial results do not include any anticipated synergies or other expected benefits from the business combinations.

Business_Segment_Information

Business Segment Information	12 Months Ended
	Dec. 31, 2014
Business Segment Information [Text Block]	4. Business Segment Information
	A summary of the business segment information for 2014 and 2013 is as follows:
			Year Ended December 31, 2014
			Medical		Marketing &
			Services		Factoring		Corporate			Total
	Revenues	$	80,614	$	3,415	$	-		$	84,029
	Cost of goods sold		-		201		-			201
	Gross Profit		80,614		3,214		-			83,828
	Operating expenses		54,438		1,909		6,648			62,995
	Income (loss) from operations	$	26,176	$	1,305	$	(6,648	)	$	20,833
	Other data:
	Depreciation and amortization expense	$	1,414	$	114	$	115		$	1,643
	Interest expense	$	-	$	23	$	265		$	288
	Income tax expense	$	480	$	-	$	-		$	480
	Intabgibles assets	$	5,945	$	13,598	$	-		$	19,543
	Goodwill	$	3,178	$	19,292	$	-		$	22,470
	Capital expenditures	$	2,023	$	-	$	-		$	2,023
	Non-cash acquisition of property	$	2,271	$	-	$	-		$	2,271
	Non-cash acquisition of intangibles and goodwill	$	7,206	$	-	$	-		$	7,206
	Investment in associates	$	150	$	-	$	-		$	150
	Total assets	$	59,751	$	43,715	$	4,116		$	107,582
	Total liabilities	$	16,995	$	11,192	$	14,094		$	42,281
	The Company’s Marketing & Factoring segment started in 2014 following the acquisition of Athas. Prior to the acquisition, the Company operated under one operating segment and therefore, has not presented a prior period comparison of segment information.

Investments_in_Associates

Investments in Associates	12 Months Ended
	Dec. 31, 2014
Investments in Associates [Text Block]	5. Investments in Associates
	In March 2014, the Company acquired an ownership interest in Group of Pioneers Diagnostics (“GOP”), LLC, representing 40% of the outstanding share interests in GOP. The investment in GOP is accounted for using the equity method of accounting. GOP owns two Management Service Organizations (“MSOs”) which provides a suite of management services to their clients which may include, but is not be limited to, general business management, fiscal management and physician practice management. GOP originated in June of 2014 and is currently undergoing efforts to achieve operational status. The carrying value of this investment at December 31, 2014 was $0.2 million, and is reflected in investments in associates on the consolidated balance sheets.
	In December 2014, as part of the Athas acquisition, the Company acquired Athas’ investment ownership in two ASC’s and one hospital: 87.5% in Elite Orthopedic and Spine Surgery Center LLC; 15.7% in Elite Sinus Spine and Ortho LLC; and 10.7% in Elite Hospital Management LLC. For these investments, the Company concluded that it did not exert significant influence over the operating and financial activities. These investments are accounted for as cost method investments and recorded at cost. The carrying value of these investments at December 31, 2014 was $.7 million, and is recorded in investments in associates in the consolidated balance sheets.

Financial_Instruments_and_Conc

Financial Instruments and Concentration	12 Months Ended
	Dec. 31, 2014
Financial Instruments and Concentration [Text Block]	6. Financial Instruments and Concentration
	In common with all other businesses, the Company is exposed to risks that arise from its use of financial instruments. This note describes the Company’s objectives, policies, and processes for managing those risks and the methods used to measure them. Further quantitative information in respect of these risks is presented throughout these consolidated financial statements.
	Principal financial instruments
	The principal financial instruments used by the Company, from which financial instrument risk arises, are as follows:
	Accounts receivable and other receivables
	Investments in associates
	Accounts payable, accrued liabilities and other current liabilities
	Other liabilities and notes payable
	Capital leases
	Lines of credit
	Debt
	The carrying amounts of the Company’s accounts receivable and other receivables, accounts payable, accrued liabilities, other current liabilities, other liabilities, capital leases, lines of credit, and debt approximate their fair values at December 31, 2014 and 2013, respectively, due to the short-term nature, maturities or nature of interest rates. Investments in associates are carried at amortized cost or their proportionate equity basis and written down to fair value if impairment is warranted.
	Financial instruments - risk management
	The Company is exposed through its operations to the following financial risks:
	Credit risk
	Fair value or cash flow interest rate risk
	Foreign exchange risk
	Other market price risk
	Liquidity risk
	Credit risk
	Credit risk is the risk of financial loss to the Company if a patient, non-partner surgeon or insurance company fails to meet its contractual obligations. The Company, in the normal course of business, is exposed mainly to credit risk on its accounts receivable from insurance companies, other third-party payors, and doctors. Accounts receivables are net of applicable bad debt reserves, which are established based on specific credit risk associated with insurance companies and payors and other relevant information.
	Liquidity risk
	Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due and arises from the Company’s management of working capital. The Company’s objective to managing liquidity risk is to ensure that it will have sufficient cash to allow it to meet its liabilities when they become due. To achieve this objective, it seeks to maintain cash balances (or agreed facilities) to meet expected requirements. The liquidity risk of the Company and its subsidiaries is managed centrally by the Company’s finance function. The Company believes that there are currently no concerns of its ability to meet its liabilities as they become due for the foreseeable future.
	A summary of certain information about our payor concentration is as follows:
	MEDICAL SERVICES SEGMENT
	PATIENT AND NET PROFESSIONAL FEEREVENUEBY PAYORS OF THENOBILIS FACILITIES
	FOR THEYEARS ENDED DECEMBER 31, 2014 AND 2013
		2014 Patient and Net	2013 Patient and Net
	Payors	Professional Fee	Professional Fee
		Revenue by Payor Mix	Revenue by Payor Mix
	Private insurance and other private pay	97.00%	92.40%
	Workers compensation	2.30%	4.50%
	Medicare	0.70%	3.10%
	Total	100.00%	100.00%
	MARKETING & FACTORING SEGMENT
	PATIENT AND NET PROFESSIONAL FEEREVENUEBY PAYORS OF THENOBILIS FACILITIES
	FOR THEYEARS ENDED DECEMBER 31, 2014 AND 2013
		2014 Patient and Net	2013 Patient and Net
	Payors	Professional Fee	Professional Fee
		Revenue by Payor Mix	Revenue by Payor Mix
	Private insurance and other private pay	100.00%	0.00%
	Workers compensation	0.00%	0.00%
	Medicare	0.00%	0.00%
	Total	100.00%	0.00%
	The patient and net professional fee revenues by payors of the Nobilis facilities for the marketing and factoring segment were 0.0% for all payors in 2013, as this segment was acquired in December 2014.
	Three facilities represent approximately 70.3% of the Company’s contracted marketing revenue and five facilities represent approximately 69.1% of the Company’s contracted marketing accounts receivable.
	CONSOLIDATED SEGMENTS
	PATIENT AND NET PROFESSIONAL FEEREVENUEBY PAYORS OF THENOBILIS FACILITIES
	FOR THEYEARS ENDED DECEMBER 31, 2014 AND 2013
		2014 Patient and Net	2013 Patient and Net
	Payors	Professional Fee	Professional Fee
		Revenue by Payor Mix	Revenue by Payor Mix
	Private insurance and other private pay	97.10%	92.40%
	Workers compensation	2.20%	4.50%
	Medicare	0.70%	3.10%
	Total	100.00%	100.00%
	Market risk
	Market risk is the risk that the fair value of future cash flows of financial instruments will fluctuate due to changes in interest rates and/or foreign currency exchange rates.
	Interest rate risk
	The Company entered into a revolving line of credit that, from time to time, may increase interest rates based on market index.
	Foreign exchange risk
	Foreign exchange risk arises because the Company has certain expenses that are incurred in Canadian dollars.
	The Company is also exposed to currency risk on purchases made from vendors based in Canada. The Company had Canadian denominated cash (“Cdn”) of $0.1 million and a nominal amount of trade payables at December 31, 2014. The Company had Cdn of $3.1 million and a nominal amount of trade payables at December 31, 2013.

Trade_Accounts_Receivable

Trade Accounts Receivable	12 Months Ended
	Dec. 31, 2014
Trade Accounts Receivable [Text Block]	7. Trade Accounts Receivable
	A detail of accounts receivable as of December 31, 2014 and 2013are as follows:
			2014			2013
	Trade accounts receivable	$	40,985		$	10,431
	Allowance for doubtful accounts		(1,391	)		(1,384	)
	Receivables transferred		(873	)		(766	)
	Receivables purchased		3,454			-
	Trade accounts receivable, net	$	42,175		$	8,281
	Trade receivables are non-interest bearing and are generally received within 30 - 90 days. Bad debt expense was nil for the years ended December 31, 2014 and 2013. The Company analyzed receivables and determined that there were no collectability issues on accounts receivable balances in the current period.
	As of December 31, 2014 and 2013, there remained a balance of $0.9 million and $0.8 million, respectively, in accounts receivable of transferred receivables pursuant to the terms of the original agreement. The Company, from time to time, shall transfer to the third party certain of its accounts receivable payments on a non-recourse basis. For the years ended December 31, 2014 and 2013, advance payment of $1.3 million and $0.4 million was received by the Company. During the same period, $7.3 million and $2.5 million of receivables was transferred. Concurrently, upon collection of these transferred receivables, payment will be made to the transferee.
	Athas purchases receivables from physicians, at a discount, on a nonrecourse basis. The discount and purchase price vary by speciality. These purchased receivables are billed and collected by Athas who retains 100% of what is collected after paying the discounted purchase price. Following the transfer of the receivable, the transferor has no continued involvement and there are no restrictions on the receivables, and as such, these transfers of receivables are accounted for as sales transactions. Gross revenue from purchased receivables was $1.6 million for the year ended December 31, 2014. Revenue, net of the discounted purchase price, was $0.9 million for the year ended December 31, 2014. Accounts receivable for purchased receivables was $3.5 million as of December 31, 2014.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property and Equipment [Text Block]	8. Property and Equipment
	Property and equipment consisted of the following as of December 31, 2014 and 2013:
			2014			2013
	Telephone equipment	$	51		$	29
	Computer hardware		510			431
	Computer software		569			444
	Furniture and office equipment		921			457
	Medical equipment		9,943			6,218
	Leasehold improvements		6,293			5,178
			18,287			12,757
	Less: accumulated depreciation		(9,200	)		(7,924	)
	Property and equipment, net	$	9,087		$	4,833
	Depreciation expense for the years ended December 31, 2014 and 2013 was $1.5 million and $0.7 million, respectively.

Intangible_Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2014
Intangible Assets [Text Block]	9. Intangible Assets
	Intangible assets at December 31, 2014 and December 31, 2013 consist of the following:
				2014										2013
		Term		Historical			Accumulated		Accumulated		Net Book			Historical		Accumulated		Accumulated		Net Book
		(in years)		Cost			Amortization		Impairment		Value			Cost		Amortization		Impairment		Value
	Definite Life
	Non-compete agreements	15-Oct	$	2,661		$	856	$	-	$	1,805		$	841	$	841	$	-	$	-
	Internally developed software	5		1,980			33		-		1,947			-		-		-		-
	Trade secret methodology	10		5,120			44		-		5,076			-		-		-		-
	Physician relationships	15 - 20		4,000			62		-		3,938			-		-		-		-
	Indefinite Life
	Tradenames			1,200			-		-		1,200			-		-		-		-
	Unfavorable lease			(290	)		-		-		(290	)		-		-		-		-
	Trademark			4,770			-		-		4,770			-		-		-		-
	Medicare license			8,498			-		7,401		1,097			8,498		-		7,401		1,097
	Total		$	27,939		$	995	$	7,401	$	19,543		$	9,339	$	841	$	7,401	$	1,097
	Amortization expense was $0.2 million and nil for the year ended December 31, 2014 and 2013, respectively. Estimated amortization expense of intangible assets is $1.2 million for the next five years and $6.7 million thereafter.

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2014
Goodwill [Text Block]	10. Goodwill
	The following table provides information on changes in the carrying amount of goodwill, which is included in the accompany consolidated balance sheets as of December 31 2014 and 2013:
			2014			2013
	Cost	$	36,770		$	15,528
	Accumulated impairment losses		(14,300	)		(14,300	)
	Total	$	22,470		$	1,228
	Cost		2014			2013
	BALANCE - beginning of period	$	15,528		$	15,528
	January 2014 business combination		701			-
	September 2014 business combination		1,249			-
	December 2014 business combination		19,292			-
	Total cost	$	36,770		$	15,528
	Accumulated impairment
	BALANCE - beginning of period	$	(14,300	)	$	(14,300	)
	Impairment charges during the period		-			-
	Total accumulated impairment	$	(14,300	)	$	(14,300	)
	The Company did not record any impairment charges for the year ended December 31, 2014 or 2013.

Lines_of_Credit

Lines of Credit	12 Months Ended
	Dec. 31, 2014
Lines of Credit [Text Block]	11. Lines of Credit
	Revolving Credit Facility for Northstar Houston Surgery Center, LLC. (“NHSC-H”)
	On November 13, 2014, NHSC-H entered into a credit agreement with Compass Bank for a $1.0 million revolving credit facility. The one-year facility requires monthly interest payments and carries an interest rate equal to the higher of (a) the Federal Funds Rate plus 0.5%, (b) LIBOR plus 1.0%, or (c) the Prime rate. Principal is due in full upon maturity at December 31, 2014, the $1.0 million facility was fully utilized. As of December 31, 2014, the Company was in full compliance with all debt covenants.
	Revolving Credit Facility for Athas
	Athas maintains a $5.0 million revolving line of credit with a financial institution. The line of credit renews annually and bears variable interest at the Prime rate plus 0.75% per annum, or a floor of 4.0% . The line of credit is collateralized by the assets of the Company and is renewable annually, subject to the approval of the financial institution. As of December 31, 2014, the balance due on the revolving line of credit was $4.4 million. As of December 31, 2014, the Company was in technical default under a continuity of operations clause which was triggered when Athas was acquired by Nobilis. Despite technical default, the debt has not been called by the bank. This line of credit is classified as current on the December 31, 2014 consolidated balance sheets.

Debt

Debt	12 Months Ended
	Dec. 31, 2014
Debt [Text Block]	12. Debt
	Purchase of Palladium for Surgery Dallas, LLC (“PFSD”)
	In conjunction with the Company’s purchase of PFSD, the Company entered into a promissory note with the Company’s Chairman for a principal amount of $2.1 million on January 1, 2011.
	The note was initially amended in March 2012, in conjunction with a private placement of common shares that occurred in January 2012.
	The note was subsequently amended in March 2013. The amended note had a principal balance of $1.7 million at December 31, 2013 bearing an interest rate at 5.25% per annum until January 2014, when the interest rate increased to 6.25% per annum. The principal amount and any accrued and unpaid interest was due on or before December 31, 2014. Interest payments were payable on a monthly basis.
	The note was then amended again in December 2014. The amended note has a principal balance of $0.4 million bearing an interest rate at 6.25% per annum. The principal amount and any accrued and unpaid interest is due on or before January 31, 2016. Outstanding interest payments have been paid as of the date of these financials.
	The note is included in the consolidated balance sheets as a long-term liability. The note has a principal balance of $0.4 million as of December 31, 2014.
	Term Loan for Athas
	Athas secured a term loan in 2011 for $0.5 million which was assumed in the acquisition (Note 2). The Company and one of the shareholders are guarantors of the loan. The loan bears interest at 4.0% per annum. The term loan requires monthly payments of principal and interest until the loan matures in May 2016. As of December 31, 2014, the balance due on the term loan was $0.1 million. The term loan is collateralized by the assets of the Company and the guarantors.
	Subordinated Notes Payable
	Athas carries subordinated notes payable which were given as consideration for working capital provided by certain individuals. The subordinated notes interest is payable semi-annually with a principal due at maturity on December 31, 2015. The notes carry a 12.0% annual interest rate and payment is subordinated to all senior secured debt instruments. The outstanding balance of the subordinated notes was $0.6 million at December 31, 2014. Some of the note holders are also employees and shareholders of the Company.
	Promissory Note for Spring Northwest Management, LLC (“SNWM”)
	In November 2013, SNWM, a consolidated entity, entered into a promissory note with Allegiance Bank Texas. The agreement provides for a $0.9 million loan which matures in November 2018. The note bears interest at a rate of 5.5% per annum and requires monthly payments of principal and interest through November 2018. The promissory note was utilized to finance the purchase of certain medical equipment, all of which serves as collateral against the note. Nobilis is not liable under the above mentioned promissory note. The note has a principal balance of $0.7 million as of December 31, 2014.
	Promissory Note for Willowbrook Imaging, LLC (“WIM”)
	In January 2014, WIM, a consolidated entity, entered into a promissory note with Branch Bank and Trust Company. The agreement provides for a $0.8 million loan which matures in February 2021. The note bears interest at a fixed rate of 3.65% per annum and requires monthly payments of principal and interest through February 2021. The promissory note was utilized to finance the purchase of certain medical equipment. Nobilis is not liable under the above mentioned promissory note. The note has a principal balance of $0.7 million as of December 31, 2014.
	Purchase of Athas
	In conjunction with the Company’s purchase of Athas, the Company entered into a promissory note with sellers for a principal amount of $12.0 million on December 1, 2014. The sellers represent the 20 previous shareholders of Athas. Payments are to be made to the sellers as follows: (a) $1.0 million payment of principal on December 31, 2014, (b) $1.0 million payment of principal on April 1, 2015, (c) consecutive monthly payments of principal and interest of $0.3 million commencing May 1, 2015 and continuing until April 1, 2018. The note accrues interest at 11% per annum. The seller agreed to defer the principal payment of $1.0 million which was due on December 31, 2014 until the Company secures financing with a commercial lender that can provide a lower cost of interest.
	Future maturities of debt as of December 31, 2014 are as follows:
	Year ending December 31,
	2015	$	4,072
	2016		4,409
	2017		4,400
	2018		1,499
	2019		274
	Total	$	14,654

Operating_Leases

Operating Leases	12 Months Ended
	Dec. 31, 2014
Operating Leases [Text Block]	13. Operating Leases
	The Company occupies five ASCs, one hospital, one urgent care clinic, one imaging center and two corporate business spaces under operating lease agreements. The Company also leases certain medical equipment. The minimum rental commitments under non-cancellable operating leases, with terms in excess of one year subsequent to December 31, 2014, are as follows:
	Year ending December 31,
	2015	$	6,737
	2016		7,114
	2017		5,917
	2018		5,748
	2019		5,202
	Thereafter		19,103
	Total future commitment		49,821
	Less: minimum sublease income to be received		(631	)
	Total future commitment, net of sublease income	$	49,190
	Rent expense was $3.5 million and $1.4 million for the years ended December 31, 2014 and 2013, respectively.

Capital_Leases

Capital Leases	12 Months Ended
	Dec. 31, 2014
Capital Leases [Text Block]	14. Capital Leases
	The Company holds various capital leases for medical equipment which contain bargain purchase options at the end of the lease terms. The remaining minimum capital lease obligations, with terms in excess of one year subsequent to December 31, 2014, are as follows:
	Year ending December 31,
	2015	$	290
	2016		290
	2017		254
	2018		51
	2019		28
	Total minimum rentals		913
	Less: total amounts representing interest		(83	)
	Capital lease obligations	$	830

Shareholders_Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2014
Shareholders' Equity [Text Block]	15. Shareholders’ Equity
	In total, the Company has issued 59,418,227 of its common shares. There is no par value assigned to our common shares.
	In December 2013, the Company issued, through a private placement agreement, 5,862,500 Units, at a price of Cdn$0.80 per Unit. Each Unit consists of one common share in the capital of the Company and one-half of one common share purchase warrant exercisable for one additional share at a price of Cdn$1.10. Through the private placement, the Company raised $4.1 million, as of December 31, 2013, net of offering costs of $0.3 million.
	Of the $4.1 million raised capital, $2.7 million was provided in exchange for stock warrants and other financial instruments, resulting in a remaining $1.4 million which was recorded as an increase to share capital for the year ended December 31, 2013.
	In August 2014, the Company elected to accelerate the expiry date of the common share purchase warrants originally issued by Nobilis as part of its unit private placement completed on December 16, 2013. Each Warrant entitled the holder thereof to purchase one additional common share of Nobilis at a price of Cdn$1.10. Nobilis received total gross proceeds of Cdn$3,224,375 from the exercise.
	In September 2014, the Company issued, through a private placement agreement, 5,568,400 Units, at a price of Cdn$1.30 per Unit. Each Unit consists of one common share in the capital of the Company and one-half of one common share purchase warrant exercisable for one additional share at a price of Cdn$1.80. Through private placement, the Company raised $6.1 million, as of September 30, 2014, net of offering costs of $0.4 million.
	Of the $6.1 million raised capital, $2.2 million was provided in exchange for stock warrants and other financial instruments, resulting in a remaining $3.9 million which was recorded as an increase to additional paid in capital in the consolidated statement of changes in shareholders’ equity.
	In December 2014, as part of the consideration given for the acquisition of Athas, the Company issued 6,666,666 shares of Nobilis common stock that are subject to a lock up of up to two years, and the issuance of an additional 4,666,666 shares of Nobilis common stock issued over two years with half issued on the first anniversary of the closing and the second half issued on the second anniversary of the closing.

Share_Based_Compensation

Share Based Compensation	12 Months Ended
	Dec. 31, 2014
Share Based Compensation [Text Block]	16. Share Based Compensation
	Restricted Share Unit Plan
	During 2008, the BOD approved the adoption of a Restricted Share Unit Plan (“RSU”) Plan for employees. Restricted Share Units (“RSUs”) may be granted to employees of Nobilis at the sole discretion of the Board of Directors (“BOD”).
	Subject to the BOD’s ability to accelerate the vesting of the RSUs if it determines circumstances so warrant, each RSU will generally vest in full on the third anniversary of the date of grant; provided that if there is a change of control of the Company prior to the vesting date of the RSUs and a participant is terminated (or resigns for good reason) within six months following such change of control, a pro rata portion of their unvested RSUs will vest up to the date of the change of control.
	Upon vesting of his or her RSUs, a participant will be entitled to receive on the vesting date, at the discretion of the BOD either: (a) a lump sum cash payment equal to the number of RSUs multiplied by an average closing price of the common shares on the Toronto Stock Exchange on the redemption date, net of any applicable deductions and withholdings; or (b) that number of common shares equal to the number of RSUs credited to the participant’s RSU account, such common shares to be issued from treasury of the Company. The participant is to receive the benefit on, or as soon as practicable after, the vesting date, but in no event later than 90 days after the vesting date. Unlike share options, RSUs do not require the payment of any monetary consideration to the Company.
	Whenever cash dividends are paid on the Company’s common shares, dividend equivalents in the form of additional RSUs will be credited to each Participant and will become part of his or her award under the RSU Plan. The RSUs representing dividend equivalents will vest and be paid at the same time and in the same manner as the RSUs to which the dividend equivalents pertain.
	In the event of a Participant’s termination of employment, voluntary or by cause, with the Company prior to any vesting date, the Participant’s rights to any unvested RSUs will be immediately and irrevocably forfeited.
	If the Participant’s employment with the Company terminates on account of death or disability or is terminated by the Company without cause prior to any vesting date, the Participant will become vested in a prorated portion of his or her unvested RSUs, based on the number of months that have elapsed in the then current vesting period as of the date of termination.
	Share Option Plan
	In April 2012, the BOD approved the adoption of a Share Option Plan for insiders, employees, and service providers. In May 2012, the Company’s shareholders approved the Share Option Plan, and in July 2012, the Toronto Stock Exchange approved the Share Option Plan. Share Options may be granted at the sole discretion of the BOD. The exercise price of an Option is determined by the BOD at the time of grant and shall not be less than the current market price. The term of each Option is determined by the BOD and shall not exceed 10 years.
	If an Optionee shall cease to be a Participant for cause, no Option held by such Optionee shall be exercisable following the date on which such Optionee ceases to be a Participant. If an Optionee ceases to be a Participant for any reason other than for cause, any Option held by such Optionee at such time shall remain exercisable in full at any time, and in part from time to time, for a period of 90 days after the date on which the Optionee ceases to be a Participant.
	If the Participant’s employment with the Company terminates on account of death, any option held by such Participant at the date of death shall be exercisable in whole or in part only by the person or persons to whom the rights of the Participant’s Options by will or laws of descent.
	The maximum number of RSUs and share options that may be issued under the combined plans is equal to 20.0% of the Company’s issued and outstanding common shares.
	The maximum number of RSUs and share options that may be issued under the combined plans is equal to 20.0% of the Company’s issued and outstanding common shares. The Company granted a total of 3,068,218 stock options during the year ended December 31, 2014. Of the granted options, 1.9 million of those vest ratably over a one to three year period while the remaining 1.2 million options vest within one month of issuance.
	The following table summarizes stock option activity for the nine months ended December 31, 2014.
			Shares			Weighted-	Weighted-Average
			Underlying			Average Exercise	Remaining Life
			Options			Price	(years)
	Outstanding at January 1, 2013		150,000		$	0.21	0.1
	Granted		1,275,000		$	0.35	9.6
	Exercised		(575,000	)	$	0.31	-
	Forfeited		(150,000	)	$	0.21	-
	Outstanding at December 31, 2013		700,000		$	0.39	9.6
	Exercisable at December 31, 2013		700,000		$	0.39	9.6
	Outstanding at January 1, 2014		700,000		$	0.39	9.8
	Granted		3,068,218		$	1.47	9.9
	Exercised		(600,000	)	$	0.3	-
	Forfeited		(50,000	)	$	1.31	-
	Outstanding at December 31, 2014		3,118,218		$	1.45	9.8
	Exercisable at December 31, 2014		220,000		$	1.16	9.6
	The total intrinsic value of stock options exercised was $0.6 million and nominal for the year ended December 31, 2014 and 2013, respectively. The total intrinsic value for all in-the-money vested outstanding stock options was $0.4 million and $0.5 million during the year ended December 31, 2014 and 2013, respectively.
	The Company recorded compensation expense relative to stock options of $1.1 million and $0.3 million for the year ended December 31, 2014 and 2013, respectively.
	The fair values of stock options used in recording compensation expense are computed using the Black-Scholes option pricing model. The table below shows the assumptions used in the model for options awarded during the year ended December 31, 2014.
			Year ended			Year ended
			31-Dec-14			31-Dec-13
	Expected price volatility		119% - 123%			124% - 125%
	Risk free interest rate		. 01% - . 05%			. 02% - . 04%
	Expected annual dividend yield		0%			0%
	Expected option term (years)		10			0.1 and 10
	Expected forfeiture rate		0%			0%
	Grant date fair value per share	$	0.97 - $1.64		$	0.29 - $0.89
	For stock options, the Company recognizes share-based compensation net of estimated forfeitures and revises the estimates in the subsequent periods if actual forfeitures differ from the estimates. Forfeiture rates are estimated based on historical experience as well as expected future behavior. As of December 31, 2014, the Company utilized a forfeiture rate of 0.0% based on a minimal number of stock option issuances, only two historical forfeitures and little to no anticipated turnover rate in those positions awarded with stock based compensation.

Noncontrolling_Interests

Noncontrolling Interests	12 Months Ended
	Dec. 31, 2014
Noncontrolling Interests [Text Block]	17. Noncontrolling Interests
	The following changes to noncontrolling interests in subsidiaries of the Company occurred during the year ended December 31, 2014 and 2013:
	Medical Ambulatory Surgical Suites, LLC (“Kirby Partnership”)
	In November 2013, the Company sold 15.1% of its ownership interest in the Kirby Partnership to existing physician limited partners, effectively decreasing the Company’s ownership interest to 25%.
	Houston Microsurgery Institute, LLC (“MSIH”)
	In March 2013, the Company redeemed the remaining equity interests held by physician limited partners at MSIH, effectively increasing the Company’s ownership interests to 97.7% . In October 2013, MSIH ceased operating as an ASC.
	Microsurgery Institute, LLC (“MSID”)
	In August 2013, the Company purchased ownership interest from all of the physician limited partners at MSID, increasing the Company’s ownership interest to 100%.
	NHC ASC – Dallas, LLC (“NHC – ASC Dallas”)
	In July 2013, the Company formed a limited liability company, NHC ASC – Dallas, which was owned 100% by Northstar Healthcare Acquisitions, LLC (“NHA”). In October 2013, the Company syndicated a private placement for certain physicians to become members in NHC ASC – Dallas. The Company assigned 100% of its equity interest in MSID to NHC ASC – Dallas, of which the Company owns 35% as a result of syndication.
	SNWM
	In January 2014, the Company acquired 31.78% ownership interest in SNWM, derived through both a direct and indirect investment. The Company also holds a 31.78% interest in both of SNWM’s fully owned subsidiaries, Spring Creek Urgent Care, LLC (“SCUC”) and Spring Creek Imaging, LLC (“SCI”).
	Spring Northwest Operating, LLC (“SNWO”)
	In January 2014, the Company acquired a 32.14% ownership in SNWO, derived through both a direct and indirect investment.
	WIM
	In January 2014, the Company acquired a 22.22% ownership interest in WIM, derived through both a direct and indirect investment.
	KIRPA Holdings, LLC (“KIRPA”)
	In January 2014, the Company acquired a 40% ownership interest in KIRPA. KIRPA holds a controlling interest in SNWM, SCUC, SCI, and SNWO.
	GRIP Medical Diagnostics, LLC (“GRIP”)
	In January 2014, the Company acquired a 40% ownership interest in GRIP. GRIP holds a controlling interest in WIM.
	Northstar Healthcare Dallas Management, LLC (“NHDM”)
	In April 2014, the Company formed a limited liability company, NHDM, which is owned 50% by NHA and 50% by physician limited partners. NHDM was formed to provide management services to NHC-ASC Dallas.
	First Nobilis
	As discussed in Note 2, in September 2014, the Company and a third party formed First Nobilis. First Nobilis is owned 51% by NHA and 49% by a third party. First Nobilis formed two subsidiary companies, First Nobilis Hospital, LLC and First Nobilis Surgical Center, LLC, as new operating entities.
	Noncontrolling interests at December 31, 2014 represent an 8.1% interest in The Palladium for Surgery – Houston, Ltd, 75% interest in the Kirby Partnership, 5% interest in MSID, 2.3% interest in MSIH, 60% interest in Houston Procedure Suite, LLC, 50% in NHDM, 50% in KIRPA, 60% in GRIP, 60% in NHC ASC – Dallas, 67.9% in SNWO, 68.2% in SNWM, 68.2% in SCUC, 68.2% in SCI; 77.8% in WIM, 49%, and First Nobilis Pursuant to U.S. GAAP, notwithstanding having an ownership interest less than 50%, the Company is deemed to have the power to control each of the above mentioned entities in which it holds less than the majority voting interests based on a combination of factors which include but are not limited to (1) the Company’s hold of majority voting rights as defined through executed partnership agreements, (2) the Company’s ability and right to govern day-to-day operations as defined through executed management and cost sharing agreements, (3) the Company’s rights as lessee on all leased facility space. Based on the power to control the activities of these entities and the responsibility to absorb significant losses, the Company was deemed the primary beneficiary under U.S. GAAP and as such consolidates these entities.

Employee_Retirement_Plan

Employee Retirement Plan	12 Months Ended
	Dec. 31, 2014
Employee Retirement Plan [Text Block]	18. Employee Retirement Plan
	Substantially all of our employees, upon qualification, are eligible to participate in our defined contribution 401(k) plan (the “Plan”). Under the Plan, employees may contribute a portion of their eligible compensation, and the Company matches such contributions annually up to a maximum percentage for participants actively employed, as defined by the Plan documents. Plan expenses were approximately $0.1 million for both the year ended December 31, 2014 and 2013. Such amounts are reflected in operating salaries and benefits in the accompanying consolidated statements of earnings.

Earnings_Per_Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Text Block]	19. Earnings Per Share
	A detail of the Company’s EPS is as follows (in thousands except for share and per share amounts) :
			2014		2013
	Net income for the period	$	7,186	$	1,198
	Issued common shares at beginning of period		42,729,547		36,082,114
	Effect of investment in subsidiary		412,787		-
	Effect of stock based compensation		403,552		470,911
	Effect of stock warrants		959,419		-
	Effect of private placement		1,464,565		240,925
	Effect of Athas acquisition		547,945		-
	W eighted average common shares at end of period		46,517,815		36,793,950
	Basic EPS	$	0.15	$	0.03
	A detail of the Company’s dilutive EPS is as follows (in thousands except for share and per share amounts):
			2014		2013
	Net income for the period	$	7,186	$	1,198
	W eighted average common shares (basic)		46,517,815		36,793,950
	Effect of stock based compensation		1,829,540		731,792
	Effect of stock warrants		50,431		111,920
	Effect of Athas acquisition		383,562		-
	W eighted average common shares (diuluted) at end of period		48,781,348		37,637,662
	Dilutive EPS	$	0.15	$	0.03

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Taxes [Text Block]	20. Income Taxes
	The following table shows the reconciliation between income tax expense reported in our consolidated statement of earnings and comprehensive income and the income tax expense that would have resulted from applying the United States federal income tax rate of 35% to pre-tax income. Though the Company was incorporated in British Columbia, all of the Company’s subsidiaries are incorporated in the United States. Therefore, the Company reconciles the income before income taxes for U.S. tax purposes.
			2014			2013
	Net income before income tax	$	20,728		$	6,851
	US federal income tax rate		35%			35%
	Expected U.S. Federal income tax (recovery)		7,254			2,398
	Permanent differences / discrete items		312			92
	State income tax (net of federal benefit)		314			115
	Valuation Allowance		(2,438	)		(620	)
	Non-controlling interests		(4,572	)		(1,917	)
	Others		(390	)		109
	Total tax expense	$	480		$	177
	The table below sets forth the tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities that are reported in our consolidated balance sheets:
			2014			2013
	Deferred tax assets:
	Goodwill	$	17,993		$	20,844
	Intangibles		1,214			1,459
	U.S. non-capital losses		14,063			12,398
	Interest carry-forward		1,391			1,391
	Non-capital losses		9,539			10,735
	Allowance for bad debts		408			406
	Reduction of carrying amount of deferred tax assets		(44,608	)		(47,233	)
	Net deferred tax assets	$	-		$	-
	Deferred tax assets are recognized to the extent that the realization of the related tax benefit through future taxable profits is probable. The Company did not recognize deferred tax assets of $44.6 million.
	The Company has Canadian non-capital losses of approximately $38.2 million which will begin to expire in 2028 and U.S. net operating losses of approximately $40.2 million which will begin to expire in 2030. On September 30, 2010 the Company issued 18,778,446 common shares to entities controlled by the Company’s Chairman resulting in a change of ownership greater than 50%. As a result, the U.S. net operating losses are limited by the Internal Revenue Code. In addition, the Company has approximately $4.0 million in interest carry-forwards that have no expiration date.

Related_Parties

Related Parties	12 Months Ended
	Dec. 31, 2014
Related Parties [Text Block]	21. Related Parties
	In conjunction with the Company’s purchase of PFSD, the Company entered into a promissory note with the Company’s Chairman, on January 1, 2011. The note had a principal balance of $0.4 million at December 31, 2014. The principal amount and any accrued and unpaid interest is due on or before January 31, 2016.
	On June 25, 2013, the Company entered into a promissory note receivable with an executive employee of the Company for a principal amount of $0.2 million. The note bears interest at a rate of 5.5% per annum. The term provides that interest will be calculated at a daily rate and all accrued and unpaid interest shall be paid annually on the first day of July of each successive year. The unpaid principal balance together with all accrued but unpaid interest is due in full on or before June 30, 2017.
	In 2013, the Company entered into a Management Services Agreement (“MSA”) with Northstar Pain Management P.A. (“NSPM”). NSPM is owned by the Company’s Chairman. Operation of NSPM is designed to support the Company’s marketing campaigns. As part of the MSA, the Company provides comprehensive management services to NSPM. At December 31, 2014, the Company is owed $0.6 million from NSPM.
	Facility lease costs associated with operating leases of approximately $0.4 million were incurred with affiliated entities during the year ended December 31, 2014.
	The minority interest holder of First Nobilis, a fully consolidated entity, is also a partial owner of First Street Hospital, L.P. (“First Street Hospital”) and First Street Surgical Center, L.P. (“First Street Surgical”), both of which have an ongoing business relationship with the Company. At December 31, 2014, the Company has a due from these related parties of $2.0 million which is partially offset by a due to related parties of $1.4 million for a net amount owed to the Company of $0.6 million. In addition, the Company leases certain medical equipment from First Street Hospital and First Street Surgical. Equipment lease costs of approximately $0.6 million were incurred during the year ended December 31, 2014.
	At December 31, 2014, three of the investors and partial owners of SNWO, WIM and SNWM owe the Company $0.2 million for their investment into the respective entities.
	Certain of the sellers of Athas are current employees of Athas, including its CEO, Chris Lloyd. The sellers of Athas entered into a promissory note with the Company for $12.0 million, as mentioned in a previous footnote.
	Certain members of the Company are also members of North American Laserscopic Spine Institute (“NALSI”). In June 2014, NALSI entered into a line of credit agreement with Athas, whereby NALSI may draw up to $0.9 million. The line of credit is subject to a 10.00% interest rate and matures on June 9, 2018. The outstanding balance as of December 31, 2014 is $0.5 million.
	Nobilis maintains certain consulting and marketing agreements with various physicians who are also equity owners in Nobilis entities. These agreements are paid directly out of those entities in which the physicians hold an ownership percentage.
	The related party transactions mentioned above are measured at exchange amounts agreed upon by both parties.

Supplemental_Cash_Flow_Informa

Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2014
Supplemental Cash Flow Information [Text Block]	22. Supplemental Cash Flow Information
	The changes in operating assets and liabilities for the years ended December 31, 2014 and 2013 are comprised of the following:
			2014			2013
	Trade accounts receivable	$	(20,958	)	$	(4,191	)
	Medical supplies		(27	)		(252	)
	Prepaids and other current assets		(2,799	)		(253	)
	Other long-term assets		466			(176	)
	Trade accounts payable and accrued liabilities		2,840			2,712
	Other current liabilities		1,340			43
	Other long-term liabilities		(8	)		(2	)
	Total	$	(19,146	)	$	(2,119	)

Litigation

Litigation	12 Months Ended
	Dec. 31, 2014
Litigation [Text Block]	23. Litigation
	The Company is involved in disputes or legal actions arising in the ordinary course of business. Management does not believe the outcome of such disputes or legal actions will have a material adverse effect on the Company’s financial position, results of operations or cash flows.
	For the year ended December 31, 2014 and 2013, the Company recorded costs of $1.1 million and $1.0 million, respectively, in connection with various legal proceedings.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Text Block]	24. Subsequent Events
	On March 31, 2015, the Company secured a $25.0 million credit facility from General Electric Capital Corporation consisting of a $20.0 million term loan and a $5 million revolving loan. The term loan bears interest at a rate of 4% plus LIBOR per annum and amortizes over 20 years with required quarterly payments of principal and interest until the loan matures in March 2020. The revolving loan also bears interest at a rate of 4% plus LIBOR per annum and amounts borrowed under the revolver may be repaid and reborrowed periodically with a maturity of March 2020. The credit facility is collateralized by the accounts receivable and physical equipment of all 100% owned subsidiaries as well as the Company’s ownership interest in all less than wholly owned subsidiaries. The new credit facility serves to refinance all previously held debt and lines of credit and provide $5.0 million for working capital. Closing costs associated with the credit facility approximated $0.6 million.
	We have evaluated subsequent events through March 31, 2015, the date the consolidated financial statements were issued.

Approval_of_Financial_Statemen

Approval of Financial Statements	12 Months Ended
	Dec. 31, 2014
Approval of Financial Statements [Text Block]	25. Approval of Financial Statements
	The consolidated financial statements were approved by the board of directors for issuance on March 31, 2015.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Basis of Presentation [Policy Text Block]	Basis of Presentation
	The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
Principles of Consolidation [Policy Text Block]	Principles of Consolidation
	Our consolidated financial statements include the accounts of Nobilis and its subsidiaries. Subsidiaries are all entities over which the Company has the power to govern the financial and operating policies through ownership of more than one half of the voting rights or by determining that the subsidiary is a variable interest entity (“VIE”) that requires consolidation. A reporting entity with a controlling financial interest in a VIE will have both of the following characteristics: (i) the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance and (ii) the obligation to absorb the losses of the VIE that could potentially be significant to the VIE or the right to receive benefit from the VIE that could potentially be significant to the VIE. See note 17 for details. All significant intercompany accounts are eliminated in consolidation.
Use of Accounting Estimates [Policy Text Block]	Use of Accounting Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Retroactively calculated third-party contractual adjustments are accrued on an estimated basis in the period in which the related services are rendered. Net patient service revenue is adjusted as required in subsequent periods based on final settlements and collections.
Cash [Policy Text Block]	Cash
	We maintain our cash in bank deposit accounts that at times, may exceed federally insured limits. We have not experienced any losses in such accounts, and we believe we are not exposed to any significant credit risks on cash. At December 31, 2014 and 2013, our cash exceeded what is federally insured.
Patient and Net Professional Fees [Policy Text Block]	Patient and Net Professional Fees
	Patient and net professional fees is reported at the estimated net realizable amounts from patients, third-party payors, and others for services rendered.
	The amounts actually collected by the Company from third-party payors, including private insurers, are variable, even for identical procedures performed. An additional factor in the determination of patient and net professional fees is the Company’s payor mix, as between private health insurance plans, workers’ compensation, directly from patients, and from government payor plans. Management reviews and evaluates historical payment data, payor mix and current economic conditions on a periodic basis and adjusts the estimated collections as a percentage of gross billings (which are used to determine patient and net professional fees) as required in subsequent periods based on final settlements and collections.
	Revenue is recognized upon the performance of the patient service and when ultimate collection is measurable and reasonably assured.
Contracted Marketing Revenues [Policy Text Block]	Contracted Marketing Revenues
	Contracted marketing revenue is comprised of payments from hospitals, ASC’s and other ancillary service providers through marketing services agreements. The services include licensing, marketing, patient intake, patient outcome assessments and educational services. Revenue is recognized on a gross basis upon the performance of the marketing service and when ultimate collection is measurable and reasonably assured. Costs associated with the performance of these services is recorded in cost of revenue in the consolidated statement of earnings.
Factoring Revenues [Policy Text Block]	Factoring Revenues
	Factoring revenue is comprised of revenue generated from certain accounts receivables which are purchased from third parties through the regular course of business. Purchase price is determined either by a flat fee per case, as dictated per the agreement, or as a percentage of final collections. At the time of purchase, the Company assumes all financial risk and incurs all costs related to collections without any recourse to the third party seller. Revenue is recognized based upon the date of the original service associated with the receivable.
Accounts Receivable [Policy Text Block]	Accounts Receivable
	Accounts receivable consists of net patient service revenues and factoring revenues recorded at net realizable value and contracted marketing revenues recorded at the fees due from the facilities for marketing services performed.
	On a periodic basis, we evaluate receivables based on the age of the receivable, history of past collections and current credit and economic conditions and adjust the carrying value accordingly. An account is written off when it is determined that all collection efforts have been exhausted. The Company does not accrue finance or interest charges on accounts receivable. An allowance for uncollectible patient receivables balances, including receivables from non-partner surgeons, is maintained at a level which the Company believes is adequate to absorb possible losses.
Medical Supplies [Policy Text Block]	Medical Supplies
	Medical supplies consist of various surgical supplies and medications and are valued at the lower of cost or market on the first-in, first-out method. The market value of inventories is determined based on the estimated selling price in the ordinary course of business less the estimated costs of sale, and a reasonable profit margin based on the effort required sell the inventories. The Company had no write-downs for medical supplies for the years ended December 31, 2014 or 2013.
Property and Equipment [Policy Text Block]	Property and Equipment
	Property and equipment is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets. Property under capital leases and the related obligation for future lease payments are initially recorded at an amount equal to the lesser of fair value of the property and equipment or the present value of the future lease payments. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to operations when incurred.
	We evaluate our long-lived assets for possible impairment annually or whenever events or changes in circumstances indicate that the carrying amount of the asset, or related group of assets, may not be recoverable from estimated future undiscounted cash flows. If the estimated future undiscounted cash flows are less than the carrying value of the assets, we calculate the amount of impairment if the carrying value of the long-lived assets exceeds the fair value of the assets. The fair value of the assets is estimated based on appraisals, established market values of comparable assets or internal estimates of future net cash flows expected to result from the use and ultimate disposition of the asset. The estimates of these future cash flows are based on assumptions and projections we believe to be reasonable and supportable. They require our subjective judgments and take into account assumptions about revenue and expense growth rates. These assumptions may vary by type of facility and presume stable, improving or, in some cases, declining results at our hospitals, depending on their circumstances.
	We report long-lived assets to be disposed of at the lower of their carrying amounts or fair values less costs to sell. In such circumstances, our estimates of fair value are based on appraisals, established market prices for comparable assets or internal estimates of future net cash flows. Gains and losses on disposals of property and equipment are determined by comparing the proceeds from disposal with the net carrying amount of property and equipment, and are recognized within other expense (income) in the consolidated statement of earnings.
	The estimated useful lives for depreciation purposes are as follows:
	Property and Equipment	Estimated Useful Lives
	Telephone equipment	7 Years
	Computer hardware	5 Years
	Computer software	3 - 5 Years
	Furniture and office equipment	7 Years
	Medical equipment	5 Years
	Leasehold improvements	Estimated usefule life or lease term
Investments in Associates [Policy Text Block]	I nvestments in Associates
	Investments in associates which are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an associate depends on an evaluation of several factors including, among others, representation on the associate’s board of directors, involvement in operations, and ownership level. Under the equity method of accounting, the associate’s accounts are not reflected within the Company’s consolidated balances sheets and statements of earnings; however, the Company’s share of the earnings or losses of the associate is reflected in other expense (income) in the consolidated statements of earnings. The Company’s carrying value in an equity method investment is reflected in investments in associates in the consolidated balance sheets.
	When the Company’s carrying value in an equity method investment is reduced to zero, no further losses are recorded in the Company’s consolidated financial statements unless the Company guaranteed obligations of the associate or has committed additional funding. When the associate subsequently reports income, the Company will not record its share of such income until it equals the amount of its share of losses not previously recognized.
	Investments in associates which are not accounted for under the equity method of accounting are accounted for under the cost method of accounting and are initially recognized at cost. Distributions received from an associate are recorded as other expense (income) in the consolidated statements of earnings. Under this method, the Company’s share of the earnings or losses of the associates is not included in the consolidated balance sheets or consolidated statements of earnings. However, the investments are reviewed for impairment at least annually and any impairment loss that is other than temporary is recognized in the consolidated statements of earnings. If circumstances suggest that the value of the associate has subsequently recovered, such recovery is not recorded. At December 31, 2014, the investments are not considered impaired.
Goodwill and Intangibles [Policy Text Block]	Goodwill and Intangibles
	Goodwill represents the excess of the cost of an acquisition over the fair value of the Company’s share of the net identifiable assets of an acquired subsidiary on the date of acquisition. Goodwill is reviewed for impairment on an annual basis or more frequently if events or circumstances indicate potential impairment. The Company’s goodwill evaluation is based on both qualitative and quantitative assessments regarding the fair value of goodwill relative to its carrying value. The Company assesses qualitative factors to determine if its sole reporting unit’s fair value is more likely than not to exceed its carrying value, including goodwill. In the event the Company determines that it is more likely than not that its reporting unit’s fair value is less than its carrying amount, quantitative testing is performed comparing recorded values to estimated fair values. Estimates of fair value are based on appraisals, established market prices for comparable assets or internal estimates of future net cash flows. If the fair value exceeds the carrying value, goodwill is not impaired. If the carrying value exceeds the fair value, an impairment charge is recognized through a charge to operations based upon the excess of the carrying value of goodwill over the implied fair value.
	Indefinite life intangible assets consisting of trade names, trademarks, Medicare licenses, and an unfavorable lease, are not amortizable; however, are evaluated for impairment on an annual basis. Definite live intangible assets consisting of non-compete agreements, internally developed software, trade secret methodology and physician relationships, are carried at cost less accumulated amortization, which is calculated on a straight-line basis over a period of five to 20 years depending on the asset’s useful life.
Advertising and Marketing Costs [Policy Text Block]	Advertising and Marketing Costs
	Advertising costs are expensed as they are incurred. Advertising expense for the years ended December 31, 2014 and 2013 was $9.9 million and $3.2 million, respectively. The Company utilizes many media outlets for marketing to patients which include internet, TV, radio, print, seminar and billboard advertising.
Income Taxes [Policy Text Block]	Income Taxes
	The tax expense for the period comprises current and deferred tax. Tax expense is recognized in the consolidated statement of earnings, except to the extent that it relates to items recognized directly in equity. For items recognized directly in equity, the tax expense is also recognized in equity.
	The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date in the countries where the Company’s subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulations is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.
	Deferred income tax is recognized, using the liability method, on temporary differences arising between the tax basis of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.
	Deferred income tax assets are recognized only to the extent that it is probable that future taxable profit will be available against which the temporary difference can be utilized.
	Deferred income tax is provided on temporary differences arising on investments in subsidiaries and associates, except where the timing of the reversal of the temporary difference is controlled by the Company and it is probable that the temporary difference will not reverse in the foreseeable future.
	Under U.S. GAAP, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty (50) percent likelihood of being realized upon ultimate settlement. The Company annually evaluates tax positions to determine the need for any additional disclosures in accordance with U.S. GAAP, including de-recognition, classification, interest and penalties on income taxes and accounting in interim periods.
Leases [Policy Text Block]	Leases
	Certain leases are classified as capital leases whenever the terms of the lease transfer substantially all of the risks and rewards of ownership to the lessee. Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases (net of any incentives received from the lessor) are charged to the consolidated statement of earnings on a straight-line basis over the period of the lease as rent expense.
Foreign Currency [Policy Text Block]	Foreign Currency
	Items included in the consolidated financial statements for each of the Company’s entities are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). Currently, all of the Company’s activities are measured using the U.S. Dollar (“USD”). The consolidated statements are presented in USD, the Company’s reporting currency.
	From time to time monetary assets and liabilities may be denominated in foreign currency, and, if so, will be translated at the exchange rate in effect as the statement of financial position date, with resulting gains or losses included within the consolidated statement of comprehensive income. Revenues and expenses denominated in foreign currencies are translated into USD at the average foreign currency exchange rate for the period.
Share Based Compensation [Policy Text Block]	Share Based Compensation
	The Company recognizes all stock-based payments to employees, including grants of employee stock options, in the consolidated financial statements based on their grant-date fair values in accordance with U.S GAAP. The Company values its stock options awarded using the Black-Scholes option pricing model. Restricted stock awards are valued at the grant date closing market price. Stock based compensation costs are recognized over the vesting period, which is the period during which the employee is required to provide service in exchange for the award. Stock-based compensation paid to non-employees are valued at the fair value at the applicable measurement date and charged to expense as services are rendered.
Net Income Per Common Share [Policy Text Block]	Net Income Per Common Share
	We calculate net income per common share by dividing net income available for common shareholders by the weighted average number of common shares outstanding during the period. Fully diluted income per share is computed using the weighted average number of common and potential common shares outstanding during the period. Potential common shares include those that may be issued upon redemption of units granted under the Company’s RSU and Share Option Plans.
Comprehensive Income [Policy Text Block]	Comprehensive Income
	Comprehensive income consists of net income and other gains and losses affecting stockholder's equity that are excluded from net income, such as unrealized gains and losses on available-for-sale investments, foreign currency translation gains and losses and minimum pension liability. The Company’s other comprehensive income represents foreign currency translation adjustments.
Noncontrolling Interests [Policy Text Block]	Noncontrolling Interests
	Noncontrolling interests are classified in the consolidated statements of earnings as part of consolidated net income and the accumulated amount of noncontrolling interest in the consolidated balance sheets as part of shareholders’ equity. Changes in the ownership interest in a consolidated subsidiary that does not result in a loss of control are accounted for as an equity transaction. If a change in ownership of a consolidated subsidiary results in a loss of control and deconsolidation, any retained ownership interests are remeasured with the gain or loss reported in net earnings.
Segment Reporting [Policy Text Block]	Segment Reporting
	The Company reports segment information based on how the chief operating decision maker, along with other members of management, organize and utilize financial and operational data in determining how to allocate resources and assess performance.
	Effective December 1, 2014, the Company’s business lines are classified into two reportable business segments which include a medical services segment and a marketing and factoring segment. The medical services segment provides the operation of hospitals, outpatient facilities and other various related health care services. The marketing and factoring segment provides direct to consumer marketing efforts which educate patients on their healthcare options. Factoring activities are included in the marketing segment, as such activities only pertain to patients which are acquired through the marketing efforts of Athas.
	We evaluate performance based on income from operations of the respective business units prior to the allocation of corporate office expenses. Transactions between segments are eliminated in consolidation. Our corporate office provides general and administrative as well as support services to our two revenue-generating segments. Management allocates costs between segments for selling, general and administrative expenses and depreciation expense.
Recent Accounting Pronouncements [Policy Text Block]	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued new guidance that introduces a new five-step revenue recognition model in which an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance also requires disclosures sufficient to enable users to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers, including qualitative and quantitative disclosures about contracts with customers, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This standard is effective for fiscal years beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently evaluating the new guidance to determine the impact it will have on its consolidated financial statements.
	In June 2014, the FASB issued amended guidance on the accounting for certain share-based employee compensation awards. The amended guidance applies to share-based employee compensation awards that include a performance target that affects vesting when the performance target can be achieved after the requisite service period. These targets are to be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant-date fair value of the award and compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved. The amendments are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. The Company does not expect adoption will have a material impact on its consolidated financial statements.
	In February 2015, the FASB issued amended guidance on the consolidation of legal entities including limited partnerships and limited liability corporations. The guidance modifies the consolidation models to be analyzed in determining whether a reporting entity should consolidate certain types of legal entities. The guidance must be applied using on of two retrospective application methods and will be effective for fiscal years beginning after December 15, 2015, and for interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The Company does not expect adoption will have a material impact on its consolidated financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Property, Plant and Equipment, Estimated Useful Lives [Table Text Block]	Property and Equipment	Estimated Useful Lives
	Telephone equipment	7 Years
	Computer hardware	5 Years
	Computer software	3 - 5 Years
	Furniture and office equipment	7 Years
	Medical equipment	5 Years
	Leasehold improvements	Estimated usefule life or lease term

Acquisitions_and_Business_Comb1

Acquisitions and Business Combinations (Tables)	12 Months Ended
	Dec. 31, 2014
Business Acquisition, Pro Forma Information [Table Text Block]			Nobilis Health			First Surgical			Athas			Consolidated
	31-Dec-14
	Revenue	$	84,029		$	17,577		$	26,059		$	127,665
	Net income before noncontrolling interests		20,247			(3,364	)		(1,481	)		15,402
	Net income attributable to noncontrolling interests		13,062			(1,275	)		-			11,787
	Net income (loss) attributable to Nobilis Health Corp.	$	7,185		$	(2,089	)	$	(1,481	)	$	3,615
	31-Dec-13
	Revenue	$	31,128		$	32,327		$	22,731		$	86,186
	Net income before noncontrolling interests		6,674			(677	)		(139	)		5,858
	Net income attributable to noncontrolling interests		5,476			2,265			-			7,741
	Net income (loss) attributable to Nobilis Health Corp.	$	1,198		$	(2,942	)	$	(139	)	$	(1,883	)
Former outpatient surgery center near Phoenix, Arizona [Member]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]			16-Dec-13
	Furniture and office equipment	$	131
	Medical equipment		495
	Leasehold improvements		2,226
	Net assets acquired		2,852
	Less : gain from bargain purchase		(2,392	)
	Total pu rchase price	$	460
Two imaging centers and one urgent care clinic in Houston [Member]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]			16-Jan-14
	Assets:
	Property and equipment	$	2,271
	Prepaid expenses and other assets		129
	Goodwill		701
	Assets acquired	$	3,101
	Liabilities:
	Accounts payable	$	697
	Debt		1,544
	Liabilities assumed	$	2,241
	Consideration:
	Cash, net of cash acquired	$	346
	Stock issued for acquisition		514
	Total Consideration	$	860
Formation of First Nobilis [Member]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]			1-Sep-14
	Assets:
	Accounts receivable	$	6,509
	Medical supplies		598
	Trade name		1,200
	Physician relationships		4,000
	Goodwill		1,249
	Assets acquired	$	13,556
	Liabilities:
	Accounts payable	$	6,060
	Unfavorable lease		290
	Liabilities assumed	$	6,350
Athas [Member]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]			1-Dec-14
	Assets:
	Cash	$	(53	)
	Trade accounts receivable		6,427
	Other receivable		450
	Prepaid expenses		226
	Investments in associates		730
	PP&E		752
	Trademark		4,770
	Internally developed software		1,980
	Non-compete agreements		1,820
	Trade secret methodology		5,120
	Goodwill		19,292
	Assets acquired	$	41,514
	Liabilities
	Trade accounts payable	$	1,531
	Accrued liabilities		3,470
	Line of credit		4,120
	Subordinated notes payable		635
	Debt		157
	Other current liabilities		102
	Other long-term liabilities		260
	Liabilities assumed	$	10,275
	Consideration:
	Cash, net of cash acquired	$	3,000
	Debt issued for consideration		12,000
	Stock issued for consideration		16,239
	Total consideration	$	31,239

Business_Segment_Information_T

Business Segment Information (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Segment Reporting Information, by Segment [Table Text Block]			Year Ended December 31, 2014
			Medical		Marketing &
			Services		Factoring		Corporate			Total
	Revenues	$	80,614	$	3,415	$	-		$	84,029
	Cost of goods sold		-		201		-			201
	Gross Profit		80,614		3,214		-			83,828
	Operating expenses		54,438		1,909		6,648			62,995
	Income (loss) from operations	$	26,176	$	1,305	$	(6,648	)	$	20,833
	Other data:
	Depreciation and amortization expense	$	1,414	$	114	$	115		$	1,643
	Interest expense	$	-	$	23	$	265		$	288
	Income tax expense	$	480	$	-	$	-		$	480
	Intabgibles assets	$	5,945	$	13,598	$	-		$	19,543
	Goodwill	$	3,178	$	19,292	$	-		$	22,470
	Capital expenditures	$	2,023	$	-	$	-		$	2,023
	Non-cash acquisition of property	$	2,271	$	-	$	-		$	2,271
	Non-cash acquisition of intangibles and goodwill	$	7,206	$	-	$	-		$	7,206
	Investment in associates	$	150	$	-	$	-		$	150
	Total assets	$	59,751	$	43,715	$	4,116		$	107,582
	Total liabilities	$	16,995	$	11,192	$	14,094		$	42,281

Financial_Instruments_and_Conc1

Financial Instruments and Concentration (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]		2014 Patient and Net	2013 Patient and Net
	Payors	Professional Fee	Professional Fee
		Revenue by Payor Mix	Revenue by Payor Mix
	Private insurance and other private pay	97.10%	92.40%
	Workers compensation	2.20%	4.50%
	Medicare	0.70%	3.10%
	Total	100.00%	100.00%
Medical services [Member]
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]		2014 Patient and Net	2013 Patient and Net
	Payors	Professional Fee	Professional Fee
		Revenue by Payor Mix	Revenue by Payor Mix
	Private insurance and other private pay	97.00%	92.40%
	Workers compensation	2.30%	4.50%
	Medicare	0.70%	3.10%
	Total	100.00%	100.00%
Marketing & Factoring [Member]
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]		2014 Patient and Net	2013 Patient and Net
	Payors	Professional Fee	Professional Fee
		Revenue by Payor Mix	Revenue by Payor Mix
	Private insurance and other private pay	100.00%	0.00%
	Workers compensation	0.00%	0.00%
	Medicare	0.00%	0.00%
	Total	100.00%	0.00%

Trade_Accounts_Receivable_Tabl

Trade Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]			2014			2013
	Trade accounts receivable	$	40,985		$	10,431
	Allowance for doubtful accounts		(1,391	)		(1,384	)
	Receivables transferred		(873	)		(766	)
	Receivables purchased		3,454			-
	Trade accounts receivable, net	$	42,175		$	8,281

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Property, Plant and Equipment [Table Text Block]			2014			2013
	Telephone equipment	$	51		$	29
	Computer hardware		510			431
	Computer software		569			444
	Furniture and office equipment		921			457
	Medical equipment		9,943			6,218
	Leasehold improvements		6,293			5,178
			18,287			12,757
	Less: accumulated depreciation		(9,200	)		(7,924	)
	Property and equipment, net	$	9,087		$	4,833

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Finite-Lived Intangible Assets [Table Text Block]				2014										2013
		Term		Historical			Accumulated		Accumulated		Net Book			Historical		Accumulated		Accumulated		Net Book
		(in years)		Cost			Amortization		Impairment		Value			Cost		Amortization		Impairment		Value
	Definite Life
	Non-compete agreements	15-Oct	$	2,661		$	856	$	-	$	1,805		$	841	$	841	$	-	$	-
	Internally developed software	5		1,980			33		-		1,947			-		-		-		-
	Trade secret methodology	10		5,120			44		-		5,076			-		-		-		-
	Physician relationships	15 - 20		4,000			62		-		3,938			-		-		-		-
	Indefinite Life
	Tradenames			1,200			-		-		1,200			-		-		-		-
	Unfavorable lease			(290	)		-		-		(290	)		-		-		-		-
	Trademark			4,770			-		-		4,770			-		-		-		-
	Medicare license			8,498			-		7,401		1,097			8,498		-		7,401		1,097
	Total		$	27,939		$	995	$	7,401	$	19,543		$	9,339	$	841	$	7,401	$	1,097

Goodwill_Tables

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Goodwill [Table Text Block]			2014			2013
	Cost	$	36,770		$	15,528
	Accumulated impairment losses		(14,300	)		(14,300	)
	Total	$	22,470		$	1,228
	Cost		2014			2013
	BALANCE - beginning of period	$	15,528		$	15,528
	January 2014 business combination		701			-
	September 2014 business combination		1,249			-
	December 2014 business combination		19,292			-
	Total cost	$	36,770		$	15,528
	Accumulated impairment
	BALANCE - beginning of period	$	(14,300	)	$	(14,300	)
	Impairment charges during the period		-			-
	Total accumulated impairment	$	(14,300	)	$	(14,300	)

Debt_Tables

Debt (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Maturities of Long-term Debt [Table Text Block]	Year ending December 31,
	2015	$	4,072
	2016		4,409
	2017		4,400
	2018		1,499
	2019		274
	Total	$	14,654

Operating_Leases_Tables

Operating Leases (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year ending December 31,
	2015	$	6,737
	2016		7,114
	2017		5,917
	2018		5,748
	2019		5,202
	Thereafter		19,103
	Total future commitment		49,821
	Less: minimum sublease income to be received		(631	)
	Total future commitment, net of sublease income	$	49,190

Capital_Leases_Tables

Capital Leases (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	Year ending December 31,
	2015	$	290
	2016		290
	2017		254
	2018		51
	2019		28
	Total minimum rentals		913
	Less: total amounts representing interest		(83	)
	Capital lease obligations	$	830

Share_Based_Compensation_Table

Share Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]			Shares			Weighted-	Weighted-Average
			Underlying			Average Exercise	Remaining Life
			Options			Price	(years)
	Outstanding at January 1, 2013		150,000		$	0.21	0.1
	Granted		1,275,000		$	0.35	9.6
	Exercised		(575,000	)	$	0.31	-
	Forfeited		(150,000	)	$	0.21	-
	Outstanding at December 31, 2013		700,000		$	0.39	9.6
	Exercisable at December 31, 2013		700,000		$	0.39	9.6
	Outstanding at January 1, 2014		700,000		$	0.39	9.8
	Granted		3,068,218		$	1.47	9.9
	Exercised		(600,000	)	$	0.3	-
	Forfeited		(50,000	)	$	1.31	-
	Outstanding at December 31, 2014		3,118,218		$	1.45	9.8
	Exercisable at December 31, 2014		220,000		$	1.16	9.6
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]			Year ended			Year ended
			31-Dec-14			31-Dec-13
	Expected price volatility		119% - 123%			124% - 125%
	Risk free interest rate		. 01% - . 05%			. 02% - . 04%
	Expected annual dividend yield		0%			0%
	Expected option term (years)		10			0.1 and 10
	Expected forfeiture rate		0%			0%
	Grant date fair value per share	$	0.97 - $1.64		$	0.29 - $0.89

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Earnings Per Share, Basic [Table Text Block]			2014		2013
	Net income for the period	$	7,186	$	1,198
	Issued common shares at beginning of period		42,729,547		36,082,114
	Effect of investment in subsidiary		412,787		-
	Effect of stock based compensation		403,552		470,911
	Effect of stock warrants		959,419		-
	Effect of private placement		1,464,565		240,925
	Effect of Athas acquisition		547,945		-
	W eighted average common shares at end of period		46,517,815		36,793,950
	Basic EPS	$	0.15	$	0.03
Schedule of Earnings Per Share, Diluted [Table Text Block]			2014		2013
	Net income for the period	$	7,186	$	1,198
	W eighted average common shares (basic)		46,517,815		36,793,950
	Effect of stock based compensation		1,829,540		731,792
	Effect of stock warrants		50,431		111,920
	Effect of Athas acquisition		383,562		-
	W eighted average common shares (diuluted) at end of period		48,781,348		37,637,662
	Dilutive EPS	$	0.15	$	0.03

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]			2014			2013
	Net income before income tax	$	20,728		$	6,851
	US federal income tax rate		35%			35%
	Expected U.S. Federal income tax (recovery)		7,254			2,398
	Permanent differences / discrete items		312			92
	State income tax (net of federal benefit)		314			115
	Valuation Allowance		(2,438	)		(620	)
	Non-controlling interests		(4,572	)		(1,917	)
	Others		(390	)		109
	Total tax expense	$	480		$	177
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]			2014			2013
	Deferred tax assets:
	Goodwill	$	17,993		$	20,844
	Intangibles		1,214			1,459
	U.S. non-capital losses		14,063			12,398
	Interest carry-forward		1,391			1,391
	Non-capital losses		9,539			10,735
	Allowance for bad debts		408			406
	Reduction of carrying amount of deferred tax assets		(44,608	)		(47,233	)
	Net deferred tax assets	$	-		$	-

Supplemental_Cash_Flow_Informa1

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]			2014			2013
	Trade accounts receivable	$	(20,958	)	$	(4,191	)
	Medical supplies		(27	)		(252	)
	Prepaids and other current assets		(2,799	)		(253	)
	Other long-term assets		466			(176	)
	Trade accounts payable and accrued liabilities		2,840			2,712
	Other current liabilities		1,340			43
	Other long-term liabilities		(8	)		(2	)
	Total	$	(19,146	)	$	(2,119	)

Company_Description_Narrative_

Company Description (Narrative) (Details)	12 Months Ended
	Dec. 31, 2014
Company Description 1	100.00%

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Narrative) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
	Y
Summary Of Significant Accounting Policies 1	20
Summary Of Significant Accounting Policies 2	$9.90
Summary Of Significant Accounting Policies 3	$3.20

Acquisitions_and_Business_Comb2

Acquisitions and Business Combinations (Narrative) (Details) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014
Acquisitions And Business Combinations 1	$2.40
Acquisitions And Business Combinations 2	0.1
Acquisitions And Business Combinations 3	0.3
Acquisitions And Business Combinations 4	431,711
Acquisitions And Business Combinations 5	0.9
Acquisitions And Business Combinations 6	51.00%
Acquisitions And Business Combinations 7	49.00%
Acquisitions And Business Combinations 8	7.5
Acquisitions And Business Combinations 9	49.00%
Acquisitions And Business Combinations 10	31.2
Acquisitions And Business Combinations 11	3
Acquisitions And Business Combinations 12	12
Acquisitions And Business Combinations 13	6,666,666
Acquisitions And Business Combinations 14	4,666,666
Acquisitions And Business Combinations 15	3.4
Acquisitions And Business Combinations 16	1.3
Acquisitions And Business Combinations 17	$0.10

Investments_in_Associates_Narr

Investments in Associates (Narrative) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Investments In Associates 1	40.00%
Investments In Associates 2	$0.20
Investments In Associates 3	87.50%
Investments In Associates 4	15.70%
Investments In Associates 5	10.70%
Investments In Associates 6	$0.70

Financial_Instruments_and_Conc2

Financial Instruments and Concentration (Narrative) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Financial Instruments And Concentration 1	0.00%
Financial Instruments And Concentration 2	70.30%
Financial Instruments And Concentration 3	69.10%
Financial Instruments And Concentration 4	$0.10
Financial Instruments And Concentration 5	$3.10

Trade_Accounts_Receivable_Narr

Trade Accounts Receivable (Narrative) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
	D
Trade Accounts Receivable 1	30
Trade Accounts Receivable 2	90
Trade Accounts Receivable 3	0
Trade Accounts Receivable 4	$0.90
Trade Accounts Receivable 5	0.8
Trade Accounts Receivable 6	1.3
Trade Accounts Receivable 7	0.4
Trade Accounts Receivable 8	7.3
Trade Accounts Receivable 9	2.5
Trade Accounts Receivable 10	100.00%
Trade Accounts Receivable 11	1.6
Trade Accounts Receivable 12	0.9
Trade Accounts Receivable 13	$3.50

Property_and_Equipment_Narrati

Property and Equipment (Narrative) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Property And Equipment 1	$1.50
Property And Equipment 2	$0.70

Intangible_Assets_Narrative_De

Intangible Assets (Narrative) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Intangible Assets 1	$0.20
Intangible Assets 2	0
Intangible Assets 3	1.2
Intangible Assets 4	$6.70

Lines_of_Credit_Narrative_Deta

Lines of Credit (Narrative) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Lines Of Credit 1	$1
Lines Of Credit 2	0.50%
Lines Of Credit 3	1.00%
Lines Of Credit 4	1
Lines Of Credit 5	5
Lines Of Credit 6	0.75%
Lines Of Credit 7	4.00%
Lines Of Credit 8	$4.40

Debt_Narrative_Details

Debt (Narrative) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Debt 1	$2.10
Debt 2	1.7
Debt 3	5.25%
Debt 4	6.25%
Debt 5	0.4
Debt 6	6.25%
Debt 7	0.4
Debt 8	0.5
Debt 9	4.00%
Debt 10	0.1
Debt 11	12.00%
Debt 12	0.6
Debt 13	0.9
Debt 14	5.50%
Debt 15	0.7
Debt 16	0.8
Debt 17	3.65%
Debt 18	0.7
Debt 19	12
Debt 20	20
Debt 21	1
Debt 22	1
Debt 23	0.3
Debt 24	11.00%
Debt 25	$1

Operating_Leases_Narrative_Det

Operating Leases (Narrative) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Operating Leases 1	$3.50
Operating Leases 2	$1.40

Shareholders_Equity_Narrative_

Shareholders' Equity (Narrative) (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2014
	USD ($)	CAD
Shareholders' Equity 1	59,418,227	59,418,227
Shareholders' Equity 2	5,862,500	5,862,500
Shareholders' Equity 3		0.8
Shareholders' Equity 4		1.1
Shareholders' Equity 5	4,100,000
Shareholders' Equity 6	300,000
Shareholders' Equity 7	4,100,000
Shareholders' Equity 8	2,700,000
Shareholders' Equity 9	1,400,000
Shareholders' Equity 10		1.1
Shareholders' Equity 11		3,224,375
Shareholders' Equity 12	5,568,400	5,568,400
Shareholders' Equity 13		1.3
Shareholders' Equity 14		1.8
Shareholders' Equity 15	6,100,000
Shareholders' Equity 16	400,000
Shareholders' Equity 17	6,100,000
Shareholders' Equity 18	2,200,000
Shareholders' Equity 19	$3,900,000
Shareholders' Equity 20	6,666,666	6,666,666
Shareholders' Equity 21	4,666,666	4,666,666

Share_Based_Compensation_Narra

Share Based Compensation (Narrative) (Details) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014
	D
	Y
Share Based Compensation 1	90
Share Based Compensation 2	10
Share Based Compensation 3	90
Share Based Compensation 4	20.00%
Share Based Compensation 5	20.00%
Share Based Compensation 6	3,068,218
Share Based Compensation 7	1,900,000
Share Based Compensation 8	1,200,000
Share Based Compensation 9	$0.60
Share Based Compensation 10	0.4
Share Based Compensation 11	0.5
Share Based Compensation 12	1.1
Share Based Compensation 13	$0.30
Share Based Compensation 14	0.00%

Noncontrolling_Interests_Narra

Noncontrolling Interests (Narrative) (Details)	12 Months Ended
	Dec. 31, 2014
Noncontrolling Interests 1	15.10%
Noncontrolling Interests 2	25.00%
Noncontrolling Interests 3	97.70%
Noncontrolling Interests 4	100.00%
Noncontrolling Interests 5	100.00%
Noncontrolling Interests 6	100.00%
Noncontrolling Interests 7	35.00%
Noncontrolling Interests 8	31.78%
Noncontrolling Interests 9	31.78%
Noncontrolling Interests 10	32.14%
Noncontrolling Interests 11	22.22%
Noncontrolling Interests 12	40.00%
Noncontrolling Interests 13	40.00%
Noncontrolling Interests 14	50.00%
Noncontrolling Interests 15	50.00%
Noncontrolling Interests 16	51.00%
Noncontrolling Interests 17	49.00%
Noncontrolling Interests 18	8.10%
Noncontrolling Interests 19	75.00%
Noncontrolling Interests 20	5.00%
Noncontrolling Interests 21	2.30%
Noncontrolling Interests 22	60.00%
Noncontrolling Interests 23	50.00%
Noncontrolling Interests 24	50.00%
Noncontrolling Interests 25	60.00%
Noncontrolling Interests 26	60.00%
Noncontrolling Interests 27	67.90%
Noncontrolling Interests 28	68.20%
Noncontrolling Interests 29	68.20%
Noncontrolling Interests 30	68.20%
Noncontrolling Interests 31	77.80%
Noncontrolling Interests 32	49.00%
Noncontrolling Interests 33	50.00%

Employee_Retirement_Plan_Narra

Employee Retirement Plan (Narrative) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Employee Retirement Plan 1	$0.10

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014
Income Taxes 1	35.00%
Income Taxes 2	$44.60
Income Taxes 3	38.2
Income Taxes 4	40.2
Income Taxes 5	18,778,446
Income Taxes 6	50.00%
Income Taxes 7	$4

Related_Parties_Narrative_Deta

Related Parties (Narrative) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Related Parties 1	$0.40
Related Parties 2	0.2
Related Parties 3	5.50%
Related Parties 4	0.6
Related Parties 5	0.4
Related Parties 6	2
Related Parties 7	1.4
Related Parties 8	0.6
Related Parties 9	0.6
Related Parties 10	0.2
Related Parties 11	12
Related Parties 12	0.9
Related Parties 13	10.00%
Related Parties 14	$0.50

Litigation_Narrative_Details

Litigation (Narrative) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Litigation 1	$1.10
Litigation 2	$1

Subsequent_Events_Narrative_De

Subsequent Events (Narrative) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
	Y
Subsequent Events 1	$25
Subsequent Events 2	20
Subsequent Events 3	5
Subsequent Events 4	4.00%
Subsequent Events 5	20
Subsequent Events 6	4.00%
Subsequent Events 7	100.00%
Subsequent Events 8	5
Subsequent Events 9	$0.60

Schedule_of_Property_Plant_and

Schedule of Property, Plant and Equipment, Estimated Useful Lives (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Summary Of Significant Accounting Policies Schedule Of Property, Plant And Equipment, Estimated Useful Lives 1	$7
Summary Of Significant Accounting Policies Schedule Of Property, Plant And Equipment, Estimated Useful Lives 2	5
Summary Of Significant Accounting Policies Schedule Of Property, Plant And Equipment, Estimated Useful Lives 3	3
Summary Of Significant Accounting Policies Schedule Of Property, Plant And Equipment, Estimated Useful Lives 4	5
Summary Of Significant Accounting Policies Schedule Of Property, Plant And Equipment, Estimated Useful Lives 5	7
Summary Of Significant Accounting Policies Schedule Of Property, Plant And Equipment, Estimated Useful Lives 6	$5

Schedule_of_Business_Acquisiti

Schedule of Business Acquisitions, by Acquisition (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Former outpatient surgery center near Phoenix, Arizona [Member]
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 1	$131
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 2	495
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 3	2,226
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 4	2,852
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 5	-2,392
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 6	460
Two imaging centers and one urgent care clinic in Houston [Member]
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 1	2,271
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 2	129
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 3	701
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 4	3,101
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 5	697
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 6	1,544
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 7	2,241
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 8	346
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 9	514
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 10	860
Formation of First Nobilis [Member]
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 1	6,509
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 2	598
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 3	1,200
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 4	4,000
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 5	1,249
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 6	13,556
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 7	6,060
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 8	290
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 9	6,350
Athas [Member]
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 1	-53
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 2	6,427
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 3	450
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 4	226
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 5	730
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 6	752
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 7	4,770
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 8	1,980
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 9	1,820
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 10	5,120
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 11	19,292
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 12	41,514
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 13	1,531
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 14	3,470
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 15	4,120
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 16	635
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 17	157
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 18	102
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 19	260
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 20	10,275
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 21	3,000
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 22	12,000
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 23	16,239
Acquisitions And Business Combinations Schedule Of Business Acquisitions, By Acquisition 24	$31,239

Business_Acquisition_Pro_Forma

Business Acquisition, Pro Forma Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 1	$84,029
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 2	17,577
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 3	26,059
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 4	127,665
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 5	20,247
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 6	-3,364
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 7	-1,481
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 8	15,402
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 9	13,062
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 10	-1,275
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 11	0
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 12	11,787
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 13	7,185
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 14	-2,089
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 15	-1,481
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 16	3,615
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 17	31,128
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 18	32,327
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 19	22,731
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 20	86,186
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 21	6,674
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 22	-677
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 23	-139
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 24	5,858
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 25	5,476
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 26	2,265
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 27	0
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 28	7,741
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 29	1,198
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 30	-2,942
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 31	-139
Acquisitions And Business Combinations Business Acquisition, Pro Forma Information 32	($1,883)

Schedule_of_Segment_Reporting_

Schedule of Segment Reporting Information, by Segment (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Business Segment Information Schedule Of Segment Reporting Information, By Segment 1	$80,614
Business Segment Information Schedule Of Segment Reporting Information, By Segment 2	3,415
Business Segment Information Schedule Of Segment Reporting Information, By Segment 3	0
Business Segment Information Schedule Of Segment Reporting Information, By Segment 4	84,029
Business Segment Information Schedule Of Segment Reporting Information, By Segment 5	0
Business Segment Information Schedule Of Segment Reporting Information, By Segment 6	201
Business Segment Information Schedule Of Segment Reporting Information, By Segment 7	0
Business Segment Information Schedule Of Segment Reporting Information, By Segment 8	201
Business Segment Information Schedule Of Segment Reporting Information, By Segment 9	80,614
Business Segment Information Schedule Of Segment Reporting Information, By Segment 10	3,214
Business Segment Information Schedule Of Segment Reporting Information, By Segment 11	0
Business Segment Information Schedule Of Segment Reporting Information, By Segment 12	83,828
Business Segment Information Schedule Of Segment Reporting Information, By Segment 13	54,438
Business Segment Information Schedule Of Segment Reporting Information, By Segment 14	1,909
Business Segment Information Schedule Of Segment Reporting Information, By Segment 15	6,648
Business Segment Information Schedule Of Segment Reporting Information, By Segment 16	62,995
Business Segment Information Schedule Of Segment Reporting Information, By Segment 17	26,176
Business Segment Information Schedule Of Segment Reporting Information, By Segment 18	1,305
Business Segment Information Schedule Of Segment Reporting Information, By Segment 19	-6,648
Business Segment Information Schedule Of Segment Reporting Information, By Segment 20	20,833
Business Segment Information Schedule Of Segment Reporting Information, By Segment 21	1,414
Business Segment Information Schedule Of Segment Reporting Information, By Segment 22	114
Business Segment Information Schedule Of Segment Reporting Information, By Segment 23	115
Business Segment Information Schedule Of Segment Reporting Information, By Segment 24	1,643
Business Segment Information Schedule Of Segment Reporting Information, By Segment 25	0
Business Segment Information Schedule Of Segment Reporting Information, By Segment 26	23
Business Segment Information Schedule Of Segment Reporting Information, By Segment 27	265
Business Segment Information Schedule Of Segment Reporting Information, By Segment 28	288
Business Segment Information Schedule Of Segment Reporting Information, By Segment 29	480
Business Segment Information Schedule Of Segment Reporting Information, By Segment 30	0
Business Segment Information Schedule Of Segment Reporting Information, By Segment 31	0
Business Segment Information Schedule Of Segment Reporting Information, By Segment 32	480
Business Segment Information Schedule Of Segment Reporting Information, By Segment 33	5,945
Business Segment Information Schedule Of Segment Reporting Information, By Segment 34	13,598
Business Segment Information Schedule Of Segment Reporting Information, By Segment 35	0
Business Segment Information Schedule Of Segment Reporting Information, By Segment 36	19,543
Business Segment Information Schedule Of Segment Reporting Information, By Segment 37	3,178
Business Segment Information Schedule Of Segment Reporting Information, By Segment 38	19,292
Business Segment Information Schedule Of Segment Reporting Information, By Segment 39	0
Business Segment Information Schedule Of Segment Reporting Information, By Segment 40	22,470
Business Segment Information Schedule Of Segment Reporting Information, By Segment 41	2,023
Business Segment Information Schedule Of Segment Reporting Information, By Segment 42	0
Business Segment Information Schedule Of Segment Reporting Information, By Segment 43	0
Business Segment Information Schedule Of Segment Reporting Information, By Segment 44	2,023
Business Segment Information Schedule Of Segment Reporting Information, By Segment 45	2,271
Business Segment Information Schedule Of Segment Reporting Information, By Segment 46	0
Business Segment Information Schedule Of Segment Reporting Information, By Segment 47	0
Business Segment Information Schedule Of Segment Reporting Information, By Segment 48	2,271
Business Segment Information Schedule Of Segment Reporting Information, By Segment 49	7,206
Business Segment Information Schedule Of Segment Reporting Information, By Segment 50	0
Business Segment Information Schedule Of Segment Reporting Information, By Segment 51	0
Business Segment Information Schedule Of Segment Reporting Information, By Segment 52	7,206
Business Segment Information Schedule Of Segment Reporting Information, By Segment 53	150
Business Segment Information Schedule Of Segment Reporting Information, By Segment 54	0
Business Segment Information Schedule Of Segment Reporting Information, By Segment 55	0
Business Segment Information Schedule Of Segment Reporting Information, By Segment 56	150
Business Segment Information Schedule Of Segment Reporting Information, By Segment 57	59,751
Business Segment Information Schedule Of Segment Reporting Information, By Segment 58	43,715
Business Segment Information Schedule Of Segment Reporting Information, By Segment 59	4,116
Business Segment Information Schedule Of Segment Reporting Information, By Segment 60	107,582
Business Segment Information Schedule Of Segment Reporting Information, By Segment 61	16,995
Business Segment Information Schedule Of Segment Reporting Information, By Segment 62	11,192
Business Segment Information Schedule Of Segment Reporting Information, By Segment 63	14,094
Business Segment Information Schedule Of Segment Reporting Information, By Segment 64	$42,281

Schedule_of_Revenue_by_Major_C

Schedule of Revenue by Major Customers by Reporting Segments (Details)	12 Months Ended
	Dec. 31, 2014
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 1	97.10%
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 2	92.40%
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 3	2.20%
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 4	4.50%
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 5	0.70%
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 6	3.10%
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 7	100.00%
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 8	100.00%
Medical services [Member]
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 1	97.00%
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 2	92.40%
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 3	2.30%
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 4	4.50%
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 5	0.70%
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 6	3.10%
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 7	100.00%
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 8	100.00%
Marketing & Factoring [Member]
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 1	100.00%
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 2	0.00%
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 3	0.00%
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 4	0.00%
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 5	0.00%
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 6	0.00%
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 7	100.00%
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 8	0.00%

Schedule_of_Accounts_Notes_Loa

Schedule of Accounts, Notes, Loans and Financing Receivable (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Trade Accounts Receivable Schedule Of Accounts, Notes, Loans And Financing Receivable 1	$40,985
Trade Accounts Receivable Schedule Of Accounts, Notes, Loans And Financing Receivable 2	10,431
Trade Accounts Receivable Schedule Of Accounts, Notes, Loans And Financing Receivable 3	-1,391
Trade Accounts Receivable Schedule Of Accounts, Notes, Loans And Financing Receivable 4	-1,384
Trade Accounts Receivable Schedule Of Accounts, Notes, Loans And Financing Receivable 5	-873
Trade Accounts Receivable Schedule Of Accounts, Notes, Loans And Financing Receivable 6	-766
Trade Accounts Receivable Schedule Of Accounts, Notes, Loans And Financing Receivable 7	3,454
Trade Accounts Receivable Schedule Of Accounts, Notes, Loans And Financing Receivable 8	0
Trade Accounts Receivable Schedule Of Accounts, Notes, Loans And Financing Receivable 9	42,175
Trade Accounts Receivable Schedule Of Accounts, Notes, Loans And Financing Receivable 10	$8,281

Schedule_of_Property_Plant_and1

Schedule of Property, Plant and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Property And Equipment Schedule Of Property, Plant And Equipment 1	$51
Property And Equipment Schedule Of Property, Plant And Equipment 2	29
Property And Equipment Schedule Of Property, Plant And Equipment 3	510
Property And Equipment Schedule Of Property, Plant And Equipment 4	431
Property And Equipment Schedule Of Property, Plant And Equipment 5	569
Property And Equipment Schedule Of Property, Plant And Equipment 6	444
Property And Equipment Schedule Of Property, Plant And Equipment 7	921
Property And Equipment Schedule Of Property, Plant And Equipment 8	457
Property And Equipment Schedule Of Property, Plant And Equipment 9	9,943
Property And Equipment Schedule Of Property, Plant And Equipment 10	6,218
Property And Equipment Schedule Of Property, Plant And Equipment 11	6,293
Property And Equipment Schedule Of Property, Plant And Equipment 12	5,178
Property And Equipment Schedule Of Property, Plant And Equipment 13	18,287
Property And Equipment Schedule Of Property, Plant And Equipment 14	12,757
Property And Equipment Schedule Of Property, Plant And Equipment 15	-9,200
Property And Equipment Schedule Of Property, Plant And Equipment 16	-7,924
Property And Equipment Schedule Of Property, Plant And Equipment 17	9,087
Property And Equipment Schedule Of Property, Plant And Equipment 18	$4,833

Schedule_of_FiniteLived_Intang

Schedule of Finite-Lived Intangible Assets (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Intangible Assets Schedule Of Finite-lived Intangible Assets 1	$10
Intangible Assets Schedule Of Finite-lived Intangible Assets 2	15
Intangible Assets Schedule Of Finite-lived Intangible Assets 3	2,661
Intangible Assets Schedule Of Finite-lived Intangible Assets 4	856
Intangible Assets Schedule Of Finite-lived Intangible Assets 5	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 6	1,805
Intangible Assets Schedule Of Finite-lived Intangible Assets 7	841
Intangible Assets Schedule Of Finite-lived Intangible Assets 8	841
Intangible Assets Schedule Of Finite-lived Intangible Assets 9	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 10	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 11	5
Intangible Assets Schedule Of Finite-lived Intangible Assets 12	1,980
Intangible Assets Schedule Of Finite-lived Intangible Assets 13	33
Intangible Assets Schedule Of Finite-lived Intangible Assets 14	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 15	1,947
Intangible Assets Schedule Of Finite-lived Intangible Assets 16	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 17	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 18	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 19	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 20	10
Intangible Assets Schedule Of Finite-lived Intangible Assets 21	5,120
Intangible Assets Schedule Of Finite-lived Intangible Assets 22	44
Intangible Assets Schedule Of Finite-lived Intangible Assets 23	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 24	5,076
Intangible Assets Schedule Of Finite-lived Intangible Assets 25	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 26	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 27	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 28	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 29	15
Intangible Assets Schedule Of Finite-lived Intangible Assets 30	20
Intangible Assets Schedule Of Finite-lived Intangible Assets 31	4,000
Intangible Assets Schedule Of Finite-lived Intangible Assets 32	62
Intangible Assets Schedule Of Finite-lived Intangible Assets 33	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 34	3,938
Intangible Assets Schedule Of Finite-lived Intangible Assets 35	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 36	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 37	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 38	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 39	1,200
Intangible Assets Schedule Of Finite-lived Intangible Assets 40	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 41	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 42	1,200
Intangible Assets Schedule Of Finite-lived Intangible Assets 43	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 44	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 45	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 46	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 47	-290
Intangible Assets Schedule Of Finite-lived Intangible Assets 48	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 49	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 50	-290
Intangible Assets Schedule Of Finite-lived Intangible Assets 51	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 52	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 53	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 54	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 55	4,770
Intangible Assets Schedule Of Finite-lived Intangible Assets 56	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 57	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 58	4,770
Intangible Assets Schedule Of Finite-lived Intangible Assets 59	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 60	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 61	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 62	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 63	8,498
Intangible Assets Schedule Of Finite-lived Intangible Assets 64	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 65	7,401
Intangible Assets Schedule Of Finite-lived Intangible Assets 66	1,097
Intangible Assets Schedule Of Finite-lived Intangible Assets 67	8,498
Intangible Assets Schedule Of Finite-lived Intangible Assets 68	0
Intangible Assets Schedule Of Finite-lived Intangible Assets 69	7,401
Intangible Assets Schedule Of Finite-lived Intangible Assets 70	1,097
Intangible Assets Schedule Of Finite-lived Intangible Assets 71	27,939
Intangible Assets Schedule Of Finite-lived Intangible Assets 72	995
Intangible Assets Schedule Of Finite-lived Intangible Assets 73	7,401
Intangible Assets Schedule Of Finite-lived Intangible Assets 74	19,543
Intangible Assets Schedule Of Finite-lived Intangible Assets 75	9,339
Intangible Assets Schedule Of Finite-lived Intangible Assets 76	841
Intangible Assets Schedule Of Finite-lived Intangible Assets 77	7,401
Intangible Assets Schedule Of Finite-lived Intangible Assets 78	$1,097

Schedule_of_Goodwill_Details

Schedule of Goodwill (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Goodwill Schedule Of Goodwill 1	$36,770
Goodwill Schedule Of Goodwill 2	15,528
Goodwill Schedule Of Goodwill 3	-14,300
Goodwill Schedule Of Goodwill 4	-14,300
Goodwill Schedule Of Goodwill 5	22,470
Goodwill Schedule Of Goodwill 6	1,228
Goodwill Schedule Of Goodwill 7	15,528
Goodwill Schedule Of Goodwill 8	15,528
Goodwill Schedule Of Goodwill 9	701
Goodwill Schedule Of Goodwill 10	0
Goodwill Schedule Of Goodwill 11	1,249
Goodwill Schedule Of Goodwill 12	0
Goodwill Schedule Of Goodwill 13	19,292
Goodwill Schedule Of Goodwill 14	0
Goodwill Schedule Of Goodwill 15	36,770
Goodwill Schedule Of Goodwill 16	15,528
Goodwill Schedule Of Goodwill 17	-14,300
Goodwill Schedule Of Goodwill 18	-14,300
Goodwill Schedule Of Goodwill 19	0
Goodwill Schedule Of Goodwill 20	0
Goodwill Schedule Of Goodwill 21	-14,300
Goodwill Schedule Of Goodwill 22	($14,300)

Schedule_of_Maturities_of_Long

Schedule of Maturities of Long-term Debt (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Debt Schedule Of Maturities Of Long-term Debt 1	$4,072
Debt Schedule Of Maturities Of Long-term Debt 2	4,409
Debt Schedule Of Maturities Of Long-term Debt 3	4,400
Debt Schedule Of Maturities Of Long-term Debt 4	1,499
Debt Schedule Of Maturities Of Long-term Debt 5	274
Debt Schedule Of Maturities Of Long-term Debt 6	$14,654

Schedule_of_Future_Minimum_Ren

Schedule of Future Minimum Rental Payments for Operating Leases (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Operating Leases Schedule Of Future Minimum Rental Payments For Operating Leases 1	$6,737
Operating Leases Schedule Of Future Minimum Rental Payments For Operating Leases 2	7,114
Operating Leases Schedule Of Future Minimum Rental Payments For Operating Leases 3	5,917
Operating Leases Schedule Of Future Minimum Rental Payments For Operating Leases 4	5,748
Operating Leases Schedule Of Future Minimum Rental Payments For Operating Leases 5	5,202
Operating Leases Schedule Of Future Minimum Rental Payments For Operating Leases 6	19,103
Operating Leases Schedule Of Future Minimum Rental Payments For Operating Leases 7	49,821
Operating Leases Schedule Of Future Minimum Rental Payments For Operating Leases 8	-631
Operating Leases Schedule Of Future Minimum Rental Payments For Operating Leases 9	$49,190

Schedule_of_Future_Minimum_Lea

Schedule of Future Minimum Lease Payments for Capital Leases (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Capital Leases Schedule Of Future Minimum Lease Payments For Capital Leases 1	$290
Capital Leases Schedule Of Future Minimum Lease Payments For Capital Leases 2	290
Capital Leases Schedule Of Future Minimum Lease Payments For Capital Leases 3	254
Capital Leases Schedule Of Future Minimum Lease Payments For Capital Leases 4	51
Capital Leases Schedule Of Future Minimum Lease Payments For Capital Leases 5	28
Capital Leases Schedule Of Future Minimum Lease Payments For Capital Leases 6	913
Capital Leases Schedule Of Future Minimum Lease Payments For Capital Leases 7	-83
Capital Leases Schedule Of Future Minimum Lease Payments For Capital Leases 8	$830

Schedule_of_Sharebased_Compens

Schedule of Share-based Compensation, Stock Options, Activity (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 1	$150,000
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 2	0.21
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 3	0.1
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 4	1,275,000
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 5	0.35
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 6	9.6
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 7	-575,000
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 8	0.31
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 9	0
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 10	-150,000
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 11	0.21
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 12	0
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 13	700,000
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 14	0.39
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 15	9.6
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 16	700,000
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 17	0.39
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 18	9.6
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 19	700,000
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 20	0.39
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 21	9.8
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 22	3,068,218
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 23	1.47
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 24	9.9
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 25	-600,000
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 26	0.3
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 27	0
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 28	-50,000
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 29	1.31
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 30	0
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 31	3,118,218
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 32	1.45
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 33	9.8
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 34	$220,000
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 35	1.16
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 36	9.6

Schedule_of_Sharebased_Payment

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 1	119.00%
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 2	123.00%
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 3	124.00%
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 4	125.00%
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 5	1.00%
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 6	5.00%
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 7	2.00%
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 8	4.00%
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 9	0.00%
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 10	0.00%
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 11	$10
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 12	0.1
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 13	10
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 14	0.00%
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 15	0.00%
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 16	0.97
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 17	1.64
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 18	0.29
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 19	$0.89

Schedule_of_Earnings_Per_Share

Schedule of Earnings Per Share, Basic (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Earnings Per Share Schedule Of Earnings Per Share, Basic 1	$7,186
Earnings Per Share Schedule Of Earnings Per Share, Basic 2	1,198
Earnings Per Share Schedule Of Earnings Per Share, Basic 3	42,729,547
Earnings Per Share Schedule Of Earnings Per Share, Basic 4	36,082,114
Earnings Per Share Schedule Of Earnings Per Share, Basic 5	412,787
Earnings Per Share Schedule Of Earnings Per Share, Basic 6	0
Earnings Per Share Schedule Of Earnings Per Share, Basic 7	403,552
Earnings Per Share Schedule Of Earnings Per Share, Basic 8	470,911
Earnings Per Share Schedule Of Earnings Per Share, Basic 9	959,419
Earnings Per Share Schedule Of Earnings Per Share, Basic 10	0
Earnings Per Share Schedule Of Earnings Per Share, Basic 11	1,464,565
Earnings Per Share Schedule Of Earnings Per Share, Basic 12	240,925
Earnings Per Share Schedule Of Earnings Per Share, Basic 13	547,945
Earnings Per Share Schedule Of Earnings Per Share, Basic 14	0
Earnings Per Share Schedule Of Earnings Per Share, Basic 15	46,517,815
Earnings Per Share Schedule Of Earnings Per Share, Basic 16	$36,793,950
Earnings Per Share Schedule Of Earnings Per Share, Basic 17	0.15
Earnings Per Share Schedule Of Earnings Per Share, Basic 18	0.03

Schedule_of_Earnings_Per_Share1

Schedule of Earnings Per Share, Diluted (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Earnings Per Share Schedule Of Earnings Per Share, Diluted 1	$7,186
Earnings Per Share Schedule Of Earnings Per Share, Diluted 2	1,198
Earnings Per Share Schedule Of Earnings Per Share, Diluted 3	46,517,815
Earnings Per Share Schedule Of Earnings Per Share, Diluted 4	36,793,950
Earnings Per Share Schedule Of Earnings Per Share, Diluted 5	1,829,540
Earnings Per Share Schedule Of Earnings Per Share, Diluted 6	731,792
Earnings Per Share Schedule Of Earnings Per Share, Diluted 7	50,431
Earnings Per Share Schedule Of Earnings Per Share, Diluted 8	111,920
Earnings Per Share Schedule Of Earnings Per Share, Diluted 9	383,562
Earnings Per Share Schedule Of Earnings Per Share, Diluted 10	0
Earnings Per Share Schedule Of Earnings Per Share, Diluted 11	48,781,348
Earnings Per Share Schedule Of Earnings Per Share, Diluted 12	$37,637,662
Earnings Per Share Schedule Of Earnings Per Share, Diluted 13	0.15
Earnings Per Share Schedule Of Earnings Per Share, Diluted 14	0.03

Schedule_of_Effective_Income_T

Schedule of Effective Income Tax Rate Reconciliation (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 1	$20,728
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 2	6,851
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 3	35.00%
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 4	35.00%
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 5	7,254
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 6	2,398
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 7	312
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 8	92
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 9	314
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 10	115
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 11	-2,438
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 12	-620
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 13	-4,572
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 14	-1,917
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 15	-390
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 16	109
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 17	480
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 18	$177

Schedule_of_Deferred_Tax_Asset

Schedule of Deferred Tax Assets and Liabilities (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 1	$17,993
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 2	20,844
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 3	1,214
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 4	1,459
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 5	14,063
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 6	12,398
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 7	1,391
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 8	1,391
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 9	9,539
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 10	10,735
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 11	408
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 12	406
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 13	-44,608
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 14	-47,233
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 15	0
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 16	$0

Schedule_of_Cash_Flow_Suppleme

Schedule of Cash Flow, Supplemental Disclosures (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 1	($20,958)
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 2	-4,191
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 3	-27
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 4	-252
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 5	-2,799
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 6	-253
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 7	466
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 8	-176
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 9	2,840
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 10	2,712
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 11	1,340
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 12	43
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 13	-8
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 14	-2
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 15	-19,146
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 16	($2,119)